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Multidrug resistance-associated protein 4 (MRP4/ABCC4) is a member of the multidrug 
resistance-associated protein (MRP) family of transporters. Like other MRPs, MRP4 is 
an organic anion transporter, but it has the unique ability to transport cyclic nucleotides 
and acyclic nucleoside monophosphate analogs such as anti-viral agents (i.e. 9-(2-
phosphonylmethoxyethyl) adenine [PMEA] and azidothymidine monophosphate [AZT]). 
Moreover, MRP4 has also been identified as a resistance factor for anti-cancer agents 
such as 6-mercaptopurine, 6-thioguanine, methotrexate and camptothecins (e.g. topotecan, 
irinotecan). Thus, due to its transport profile, the up-regulation of MRP4 may have a 
serious impact on the efficacy of nucleoside-based anti-viral treatments and anti-cancer 
chemotherapy.  
 
To date, the transport properties of human MRP4 (hMRP4) protein has been fairly well 
characterized. However, the same is not true for the regulation of the expression of the 
human MRP4 gene. Numerous in vivo and in vitro studies suggest that MRP1, MRP2 and 
MRP3 are regulated transcriptionally by nuclear receptors (NRs). In addition, several 
animal studies have provided evidences that MRP4 can be regulated by nuclear receptors. 
Hence, this study aims to examine the role of xenobiotic-activated NRs in the 
transcriptional regulation of hMRP4. Treatment of human hepatocarcinoma derived 
HepG2 and Huh7 cells indicates that hMRP4 can be transcriptionally induced by AhR 
activators (e.g. â-Napthoflavone and 3-Methylcholanthrene), RAR activators (e.g. all-
trans retinoic acid and 13-cis retinoic acid) as well as PXR activator (e.g. Pregnenolone-
16á-carbonitrile). All the xenobiotics used did not affect cell viability. Transient 
 x
transfection of the hMRP4 5-flanking region-luciferase reporter construct also produced 
similar responses to the same AhR, RAR, PXR activators. In addition, the induction of 
the hMRP4 promoter was dependent on the dose of the activators and the level of 
expression of the corresponding nuclear receptor.  
 
Analysis of the promoter region using the MatInspector program led to the prediction of 
the presence of putative AhR, RAR and PXR response elements on the promoter. 
Deletion or mutation of each of the predicted response elements was carried out and this 
led to the identification of two AhR response elements (AREs) at -2126/-2120 and -
1452/-1446, a RAR response element (RRE) at -1764/-1759 and a PXR response element 
(PRE) at -1225/-1215 on the promoter of the hMRP4 gene. In conclusion, our present 
findings provide evidences to suggest that hMRP4 promoter can be activated by 
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1.1. Clinical Implications of Multidrug Resistance Proteins 
Multidrug resistance (MDR) describes the phenomenon of simultaneous resistance to a 
wide spectrum of structurally unrelated drugs (Ling, 1997). Many studies involving the 
use of cell lines and transplantable tumors have demonstrated that MDR can develop 
rapidly. The various mechanisms of MDR identified to date include reduced drug 
accumulation involving decrease uptake or increase excretion; increased drug 
detoxification involving phase II drug metabolizing enzymes (e.g. glutathione-S-
transferase); altered targets involving topoisomerase II; and  drug-induced apoptosis 
involving genes in the Bcl-2 pathway (Ling, 1997). Several of these pathways can lead to 
MDR, in which cells acquire resistance to several drugs in additional to the initial 
therapeutic compound. The mechanism of MDR that is of relevance to this study 
involved the expression of the membrane proteins that efflux a variety of compounds out 
of target cells resulting in the reduced drug accumulation. 
 
Several reviews have concluded that the ATP-binding cassette (ABC) transporter 
superfamily plays important roles in MDR (Dean et al., 2001; Adachi et al., 2002; Kruh 
and Belinsky, 2003; Scotto, 2003; Chan et al., 2004; Choudhuri and Klaassen, 2006). The 
ABC transporter superfamily contains membrane proteins that translocate a variety of 
substrates across extra- and intra-cellular membranes against a concentration gradient at 
the cost of ATP hydrolysis (Choudhuri and Klaassen, 2006). These transporters, being 
able to transport exogenous and endogenous compounds, function to reduce the body 
load of potentially harmful substances. However, one by-product of this protective 
 2
function is the ability to eliminate various useful drugs from the body, causing drug 
resistance. 
 
To date, there are 49 known mammalian ABC transporter genes. These genes are further 
classified into subfamilies A to G based on similarity in gene structure, order of the 
domains and on sequence homology in the nucleotide binding domains (NBDs) and 
membrane spanning domains (MSDs) (Choudhuri and Klaassen, 2006). Of interest to this 
study is the ABC subfamily C (ABCC) which consists of 12 members, nine of which are 
multidrug resistance associated proteins (MRP 1 ; ABCC1), MRP2 (ABCC2), MRP3 
(ABCC3), MRP4 (ABCC4), MRP5 (ABCC5), MRP6 (ABCC6), MRP7 (ABCC10), 
MRP8 (ABCC11), MRP9 (ABCC12) (Dean and Allikmets, 2001; Kruh and Belinsky, 
2003).  
 
Since the discovery of MRPs, they have gained increasing clinical importance by virtue 
of their broad spectrum of substrate specificity for multiple anti-cancers agents and their 
documented over-expression observed in cancers such as leukemia, breast, bladder and 
colorectal cancers (Bera et al., 2001; Bera et al., 2002; Ohishi et al., 2002; Burger et al., 
2003; Diestra et al., 2003; Kruh and Belinsky, 2003). MDR phenomenon resulted from 
the expression of these efflux transporters is therefore a major obstacle in effective cancer 
chemotherapy.  
 
In addition to the efflux of anti-cancer agents, MRPs are also implicated in the efflux of 
anti-viral compounds such as 9-(2-phosphonylmethoxyethyl) adenine (PMEA) as well as 
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other nucleoside-based anti-viral drugs (Schuetz et al., 1999; Adachi et al., 2002). For 
instance, it was demonstrated that the efficacy of anti-viral inhibition of HIV replication 
was markedly impaired in MRP4 expressing cells and this was directly linked to 
enhanced efflux (Hatse et al., 1998; Adachi et al., 2002).  Hence, high levels of MRP4 
expression could possibly be one of the reasons behind reduced clinical efficacies of 
these drugs in anti-viral treatments. 
 
 
1.2. Multidrug Resistance Associated Proteins (MRPs) 
In 1976, Juliano and Ling reported that the over-expression of a 170kDa membrane 
protein, called P-glycoprotein (Pgp) / MDR1, conferred resistance to a wide array of 
amphiphilic drugs in colchicine-resistant Chinese hamster ovary cells. Tremendous 
efforts were made for many years to characterize the function and regulation of this 
founding member of the ABC family of drug transporters, in hope that its inhibition 
would be the key solution to overcome clinical resistance to multiple anti-cancer agents 
(Scotto, 2003). However in 1992, Cole et al discovered a second type of drug pump in 
MDR cancer cells now known as the multidrug resistance associated protein 1 (MRP1). 
This 190kDa founding member of the ABC subfamily C revealed that MDR is 
considerably more complex than previously believed. Since then, other members of the 
subfamily have been subsequently identified and characterized. 
 
As mentioned above, the ABC subfamily C (ABCC) consists of 12 members, ABCC 1 
through ABCC 12. Of these, ABCC 1-6 (MRP 1-6), ABCC 10 (MRP 7), ABCC 11 
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(MRP 8) and ABCC 12 (MRP 9) are transporters. The other three members are the cystic 
fibrosis transmembrane conductance regulator (CFTR/ABCC 7, a Cl- channel) and two 
sulfonylurea receptors, ABCC 8 (SUR1) and ABCC 9 (SUR2) (Dean and Allikmets, 
2001; Kruh and Belinsky, 2003). 
 
All MRPs have a conserved core region of two nucleotide binding domains (NBDs), two 
membrane spanning domains (MSDs) each composed of six transmembrane helices and a 
linker segment (L1) located between NBD1 and MSD2 (Figure 1.1). Analyses of the 
predicted structures of all nine MRPs indicated that not all of them possess MSD0 
domains (Belinsky et al., 1998). MRP4, 5, 8 and 9 lack the third membrane spanning 
domain (MSD0) but possess L0 domains, while MRP2, 3, 6 and 7 resemble MRP1 (Bera 
et al., 2001; Hopper et al., 2001; Tammur et al., 2001) (Figure 1.1). Despite the 
differences, all MRPs are lipophilic anion pumps that possess the ability to confer 
resistance to anti-cancer agents (Kruh and Belinsky, 2003). 
 
Although all the nine MRPs possess a common core structure, they evolved to have 
rather different substrate specificity. Collectively, the MRPs are able to transport an array 
of structurally diverse lipophilic anions and function as xenobiotics efflux pumps. These 
lipophilic anions include endogenous substrates such as cyclic nucleotides, bile acids, 
leukotrienes, glutathione and glucuronide conjugates and exogenous substrates such as 
nucleoside analogs, antifolates as well as other classes of anti-cancer and anti-viral agents. 
The properties of each MRP are summarized in Table 1.1 and their individual transport 




Figure 1.1. Two dimensional membrane topology models for P-glycoprotein (Pgp) 
and MRP family members. 
Topological model for MRP1 (which resembles MRP2, MRP3, MRP6 and MRP7) (top) 
and MRP4 (which resembles MRP5, MRP8 and MRP9) (bottom). MRP1 is characterized 
by the presence of an extra MSD (MSD0). NBD, nucleotide binding domain; MSD, 
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1.3. Transport Functions of MRP Family Members 
1.3.1. MRP1 
The substrate selectivity of MRP1 is broad. It is involved in glutathione homeostasis and 
in inflammatory processes involving leukotriene C4 (LTC4). It is an important transporter 
for a variety of organic anion conjugates such as glutathione conjugates (e.g. LTC4), 
glucuronides (e.g. bilirubin glucuronide) as well as glutathione disulfide (GSSG), 
unconjugated anionic drugs and dyes (Choudhuri and Klaassen, 2006). It is also reported 
that MRP1 is able to co-transport GSH and unconjugated amphipathic neutral/basic drugs 
or GSH and arsenite oxyanions (Zaman et al., 1995). MRP1 is also able to confer 
resistance to anthracyclines (such as doxorubicin and daunorubicin), epipodophyllotoxins 
(such as teniposide and etoposide), vinca alkaloids (such as vincristine and vinblastine), 
camptothecins (such as topotecan) and methotrexate but not to taxanes (Kruh and 
Belinsky, 2003).  
 
1.3.2. MRP2 
Studies in hepatocytes have demonstrated that MRP2 (a canalicular transporter) is 
involved in exporting a variety of conjugated and unconjugated compounds into bile. The 
substrate specificity of MRP2 is similar to that of MRP1 and it includes glutathione 
conjugates (e.g. LTC4), glucuronides (e.g. bilirubin glucuronide) and a number of drugs 
and drug metabolites (Kawabe et al., 1999). In vitro studies also showed that the drug 
resistance profile of MRP2 is similar to that of MRP1 for anthracyclines, 
epipodophyllotoxins, vinca alkaloids and camptothecins (Kawabe et al., 1999). In 
addition, MRP2 confers resistance to cisplatin, which forms toxic glutathione conjugates 
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in the cell (Ishikawa and Ali-Osman, 1993). It is worth noting that cisplatin resistance has 
never been seen in MRP1 over-expressing cells (Borst et al., 2000). MRP2 also transports 
various constituents in food, such as dietary flavonoids quercetin 4-â-glucoside and 
sulphate conjugates of the tea flavonoid epicatechin (Choudhuri and Klaassen, 2006) as 
well as sulfated bile acids such as taurochenodeoxycholate-3-sulfate (Akita et al., 2001).  
 
1.3.3. MRP3 
MRP3 shares considerable substrate specificity with MRP1, MRP2 and bile salt export 
pump (BSEP/ABCB11) but have significantly lower affinity for substrates that are also 
transported by MRP1 and MRP2 (Zeng et al., 2000). MRP3 does not transport GSH 
hence it does not confer resistance to anti-cancer drugs that are co-transported with GSH 
by MRP1 and MRP2. In addition, MRP3 can confer resistance to etoposide, teniposide, 
vincristine and methotrexate but is less efficient than MRP1 and MRP2 (Zeng et al., 
2000). MRP3 is also able to transport glutathione and glucuronide conjugates as well as 
both unconjugated and conjugated bile acids including monoanionic bile acids such as 
taurocholate and glycocholate, which constitute a significant component of human and 
rodents bile acid pool (Hirohashi et al., 2000; Zeng et al., 2000).  The ability of MRP3 to 
transport non-sulfated bile acids is a characteristic not shared by MRP1 and MRP2. The 
fact that MRP3 transport glucuronide conjugates (such as estradiol-17â-glucuronide 
[E217âG]), indicates that MRP3 may contribute to the efflux transport of 




1.3.4. MRP4 & MRP5 
MRP4 is an organic anion transporter that has been shown to transport endogenous 
substrates such as E217âG, cAMP, cGMP, prostanoids, steroids and bile acids (Chen et 
al., 2001; Chen et al., 2002; Zelcer et al., 2003). In transport studies, it was demonstrated 
that MRP4 can also function as an efflux pump for prostaglandin E2 (PGE2), 
thromboxane B2 (TXB2) and prostaglandin F2á (PGF2á) (Rius et al., 2005).  In addition to 
that, the same group recently showed that human MRP4 can also mediate ATP-dependent 
co-transport of GSH and taurocholate (Rius et al., 2006). Zelcer et al (2003) showed that 
MRP4 can transport dehydroepiandrosterone 3-sulfate (DHEAS) (among the highest 
steroid levels in human blood), with much higher affinity than other MRPs that have been 
shown to transport it (Zelcer et al., 2003). Human MRP4 has also been shown to confer 
resistance to camptothecins (e.g. topotecan, irinotecan and SN-38), anti-cancer base 
analogs (e.g. 6-mercaptopurine and thioguanine), antifolates (such as methotrexate) and 
anti-viral drugs (such as PMEA and azidothymidine monophosphate (AZT)) (Borst et al., 
2000; Chen et al., 2002; Tian et al., 2005). 
 
MRP5 is structurally similar to MRP4. Hence it is not surprisingly to note that they have 
overlapping substrate specificity. Like MRP4, MRP5 can transport cAMP and cGMP as 
well as confer resistance to anti-cancer base analogs (e.g. 6-mercaptopurine and 
thioguanine) and anti-viral drugs (such as PMEA and AZT) (Choudhuri and Klaassen, 
2006). However, MRP5 does not confer resistance to other anti-cancer drugs tested (e.g. 
anthracyclines, vinca alkaloids, epipodophyllotoxins or methotrexate) (Borst et al., 2000). 
It has also been shown that MRP5 can mediate efflux of 2, 3-didehydro-2, 3-
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dideoxythymidine 5-monophosphate (d4TMP), a pyrimidine-based anti-viral (2, 3-
dideoxynucleoside) and its phosphoramidate derivative alaninyl-d4TMP (Wijnholds et al., 
2000). Such a property has not been reported for MRP4. 
 
1.3.5. MRP6 
Initial experiments using Chinese hamster ovary (CHO) cells over-expressing MRP6 
demonstrated that MRP6 can transport many glutathione-conjugate substrates that are 
also transported by MRP1 to MRP3, such as etoposide, doxorubicin and cisplatin 
(Belinsky et al., 2002). However, transport of other known MRP substrates including 
vinblastine, vincristine and paclitaxel was not demonstrated (Belinsky et al., 2002). 
Belinsky et al (2002) also reported that MRP6 can facilitate the transport of LTC4 and 
Dinitrophenyl-S-glutathione (DNP-SG) but not E217âG. These data suggest a role for 
MRP6 in drug transport in tissues where it is expressed, including liver and kidney. 
However, the importance of MRP6 in conferring drug resistance has yet to be determined. 
It is also worth noting that MRP6 deficiency is linked to the genetic disorder 
pseudoxandoma elasticum, a rare autosomally inherited connective tissue disease, but the 
cause-and-effect relationship has yet to be uncovered (Kruh and Belinsky, 2003). 
 
1.3.6. MRP7, MRP8 and MRP9 
Relatively little is known about these three MRP transporters. It has been shown that 
MRP7 transports E217âG and LTC4 with low affinity. However, the transport of other 
established substrates of MRP family transporters has not been detected (Chen et al., 
2003). MRP7 appears to confer very high level of resistance to a class of anti-cancer 
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drugs, the taxanes such as docetaxel and paclitaxel (Hopper-Borge et al., 2004). This is 
an interesting finding because MRP7 is the only member of the MRP family known to 
confer resistance to taxanes. Human MRP8 and MRP9 are found to be expressed at high 
levels in breast cancer (Bera et al., 2001; Bera et al., 2002). MRP8 is highly homologous 
with MRP5. Hence, it is not surprising that MRP8 has overlapping substrate profile with 
MRP5. Studies with MRP8 over-expressing cells indicated that MRP8 can confer 
resistance to a range of clinically relevant nucleoside analogs, including the anti-cancer 
fluoropyrimidines such as 5-fluorouracil, 5-fluoro-2-deoxyuridine and 5-fluoro-5-
deoxyuridine, anti-human immunodeficiency virus drug (e.g. 2, 3-dideoxycytidine) and 
the anti-hepatitis B agent (i.e. PMEA) (Guo et al., 2003). The involvement of MRP9 in 
drug resistance or drug transport has yet to be fully characterized, but its structural 
resemblance to MRP4, MRP5 and MRP8 raises the possibility that it may share some of 






Table 1.1. Characteristics of MRPs 
Name Symbol Membrane Localization Physiological Substrates Exogenous Substrates Physiological Functions 





Glutathione homeostasis; Transporter for 
glutathione conjugates & Inflammatory 
processes involving leukotrienes 
MRP2 ABCC2 Apical 
Sulfated bile acids,  LTC4, 




Vinca alkaloids, Camptothecins,  
Detoxification via hepatobiliary excretion 
metabolites into bile 
MRP3 ABCC3 Basolateral 
Sulfated, Conjugated & 
unconjugated bile acids, 
Glutathione & Glucuronide 
conjugates 
Etoposide, teniposide, vincristine 
and methotrexate 
Efflux transport of toxic agents detoxified 
by glucuronidation; backup basolateral 





E217âG, cAMP, cGMP, 
prostanoids, steroids and 
bile acids 
Camptothecins , Anti-cancer base 
analogs, antifolates and anti-
retroviral drugs, methotrexate 
Transport system for DHEAS and/or 
other structurally related steroids 
MRP5 ABCC5 Basolateral cAMP, cGMP, Glutathione 
conjugates 
Anti-cancer base analogs, anti-
retroviral drugs and pyrimidine-
based antiviral 
Unknown 
MRP6 ABCC6 Basolateral Glutathione conjugates Etoposide, Doxorubicin & Cisplatin Connective Tissue Homeostasis 
MRP7 ABCC10 Unknown E217âG & LTC4 Taxanes Unknown 
MRP8 ABCC11 Unknown 
E217âG, LTC4, cAMP, 
cGMP, glycocholate & 
taurocholate 
Nucleoside analogs (Anti-cancer, 
Anti-viral agents) 
Secretion of aliphatic or aromatic 
hydrocarbon constituents of earwax; 
Single nucleotide polymorphism (180Gly 
→ Arg) determines wet vs. dry earwax 
MRP9 ABCC12 Unknown Unknown Unknown Unknown 
 12
1.4. MRP4 
Of interest to this study is the MRP4 transporter. Together with MRP3 and MRP5, MRP4 
was first identified as a new member of the MRP family in 1997 when the expressed 
sequence tag database was screened for new MRP family members that might be linked 
to the drug resistant phenotype (Kool et al., 1997). The MRP4 gene is located on 
chromosome 13q32.1 and contains 31 exons encoding 1325 amino acids (Lee et al., 
1998). Similar to MRP5, MRP4 is a considerably smaller transporter than MRP1, MRP2, 
MRP3, MRP6 and MRP7 because of the absence of the MSD0 domain (Figure 1.1). 
MRP4 is predicted to contain 12 trans-membrane helices grouped into two MSDs and 
possess a typical ABC transporter structure with four domains (Belinsky et al., 1998; Lee 
et al., 1998). MRP4 transcripts have been found in several tissues including prostate, 
liver, testis, ovary, brain, kidney, intestine, adrenal glands and a number of cell lines (Lee 
et al., 1998; Chen et al., 2001; Ritter et al., 2005). Based on immunohistochemical 
analysis, MRP4 protein has been detected in prostate in the basolateral membrane of 
tubuloacinar cells (Lee et al., 2000) and in kidney in the proximal tubule apical 
membrane (van Aubel et al., 2002).  In liver, MRP4 is localized at the sinusoidal 
(basolateral) membrane of the hepatocytes (Rius et al., 2003). In addition, MRP4 was 
detected in astrocytes and in the luminal (apical) side of the capillary endothelium (Nies 
et al., 2004). The fact that MRP4 can have either apical or basolateral localization 
depending on the tissues examined, implies that MRP4 can have different and unique 




1.4.1. MRP4-mediated Transport 
Lipid membranes are virtually impermeable to cyclic nucleotides, but the appearance of 
these intracellular signal molecules in blood and urine has been known for decades 
(Ashman et al., 1963). MRP4 is implicated in the transport of cyclic nucleotides based on 
various observations. Firstly, using isolated membrane vesicles, MRP4 has been 
identified as an ATP-dependent export pump for the transport of cyclic nucleotides 
(cAMP and cGMP) which are important cellular signaling molecules (Chen et al., 2001). 
This thus suggests that MRP4 might be involved in the regulation of the intracellular 
concentration of these important second messengers. Secondly, increased efflux of cAMP 
has been observed in MRP4-overexpressing HepG2 cells (Lai and Tan, 2002) while 
increased efflux of both cAMP and cGMP have been observed in MRP4-overexpressing 
HEK293 cells (Wielinga et al., 2003). The precise physiological role of cyclic nucleotide 
efflux is not completely understood. However, in mammals, it is believed that the efflux 
of cyclic nucleotides serves two functions. One possible function is to modulate cyclic 
nucleotide signaling by removing excess intracellular cyclic nucleotides. This efflux may 
serve as an alternative elimination pathway to degradation by phosphodiesterases. 
However, attenuation of elevations of these second messengers is believed primarily to 
be enzyme-mediated, by the action of phosphodiesterases, to allow precise time-sensitive 
signaling. In contrast, the cellular efflux of these second messengers by MRP4 is believed 
to be slower and effective only at high intracellular concentrations (Adachi et al., 2002). 
Thus, the physiological impact of MRP4 in this process remains to be elucidated. A 
second possible function is to provide extracellular cAMP involved in extracellular 
signaling and intercellular signaling (Ritter et al., 2005). 
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The capability of MRP4 and MRP5 to transport cyclic nucleotides appears to underlie the 
distinct drug resistance profiles of these pumps. Unlike MRP1-3, MRP4 and MRP5 do 
not confer resistance to natural products agents such as anthracyclines, vinca alkaloids or 
epipodophyllotoxins, but instead have the ability to confer resistance to certain 
nucleoside analogs (Kruh and Belinsky, 2003). MRP4 gained clinical importance in 
recent years because of its ability to transport acyclic nucleoside monophosphate analogs 
such as PMEA and AZT, which are employed in the treatment against hepatitis B virus 
and human immunodeficiency virus respectively (Robbins et al., 1995; Schuetz et al., 
1999; Lee et al., 2000). Besides these analogs, MRP4 has also been shown to mediate 
resistance to the anti-viral agent ganciclovir (Adachi et al., 2002). Thus, the ability of 
MRP4 to export and confer resistance to these anti-viral agents is likely to impact on the 
cytotoxicity of these agents and their ability to inhibit viral replication. 
  
Analysis of transfected cell lines revealed that MRP4 and MRP5 have not only able to 
confer resistance to anti-viral drugs, but were also resistance factors for anti-cancer 
agents such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG), and in the case of 
MRP4, methotrexate (MTX) as well as camptothecins (e.g. topotecan, irinotecan and SN-
38) (Lee et al., 2000; Wijnholds et al., 2000; Chen et al., 2002). 6-MP and 6-TG are 
purine derived anti-cancer agents which are currently important in the treatment of acute 
lymphoblastic leukemia (ALL) (De Abreu et al., 2000). In general, the finding that 
MRP4 over-expression confers resistance to anti-cancer agents has strong clinical 
implications for cancer chemotherapy. Indeed, many studies have found associations 
between elevated MRP4 expression and multidrug resistant phenotypes observed in blood 
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cancers such as ALL as well as other solid tumors (Sampath et al., 2002). For instance, 
MRP4 over-expression has been found to be significantly associated with poor clinical 
outcome in aggressive primary neuroblastoma treated with irinotecan (Norris et al., 2005). 
In addition, the expression of MRP4 in metastatic ovarian carcinoma and small cell lung 
cancer has been linked to tumor resistance against topotecan, a semisynthetic water-
soluble derivative of camptothecin (Tian et al., 2006).  
 
Similar to MRP1 and MRP2, MRP4 can also mediate the export of reduced glutathione 
(GSH). Using MRP4 over-expressing HepG2 cells, it has been demonstrated that GSH is 
required for the co-transport of cAMP, suggesting that GSH plays a role in MRP4 
functions (Lai and Tan, 2002). In addition, human MRP4 has also been shown to co-
transport monoanionic bile acids such as glycocholate, taurocholate and cholate, together 
with GSH (Rius et al., 2003). Several clinical studies have shown that the MRP4 protein 
is up-regulated in patients with cholestasis (Gradhand et al., 2007; Zollner et al., 2007). 
Cholestatic liver disease is characterized by systemic intracellular accumulation of 
potentially toxic biliary constituents such as bile acids and bilirubin, resulting in liver 
damage and jaundice (Wagner et al., 2005). Hence, the observed adaptive induction of 
basolateral export pumps (e.g. MRP3 and MRP4) under cholestatic conditions implies 
that these pumps serve as an alternative elimination route for elevated bile acids and 
bilirubin in order to prevent hepatotoxicity (Schrenk et al., 2001; Wagner et al., 2005). In 
addition to the transport of cyclic nucleotides, nucleoside analogs, glucuronide and 
glutathione conjugates, reduced glutathione and bile acids, MRP4 can also transport 
prostaglandins (Rius et al., 2005) and sulfated steroid conjugates (e.g. DHEAS) (Zelcer et 
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al., 2003), indicating their role in inflammatory responses and hormone homeostasis 
respectively. 
 
1.4.2. Regulation of MRP4 Expression 
MRP4 was first suggested to play a role in the adaptive response to hepatic overload of 
bile acids following the genetic deletion of the bile acid sensor, farnesoid X receptor 
(FXR) (Sinal et al., 2000). In subsequent studies, MRP4 has been reported to be up-
regulated in both rats and mice after bile duct ligation (Wagner et al., 2003; Denk et al., 
2004) as well as in patients with progressive familial intrahepatic cholestasis (PFIC) and 
primary biliary cirrhosis (PBC) (Keitel et al., 2005; Zollner et al., 2007). To date, the 
mechanism of MRP4 induction has not been fully elucidated. Currently, studies on the 
gene regulation of MRP4 have been mainly conducted on MRP4 orthologs in rat and 
mouse models. It was reported that biliary obstruction induces a pronounced up-
regulation of MRP4 in mouse liver and kidney (Wagner et al., 2003). However in rats, 
MRP4 protein is only up-regulated in the liver but down-regulated in the kidney (Denk et 
al., 2004). This up-regulation of MRP4 was even more pronounced in FXR-/- mice 
implying an FXR-independent mechanism (Wagner et al., 2003). In addition, animal 
studies conducted in mice revealed that murine hepatic MRP4 mRNA can be up-
regulated by peroxisome proliferator-activated receptor á (PPARá) and constitutive 
androstane receptor (CAR) when subjected to clofibrate and 1, 4-bis[2-(3, 5-
dichloropyridyloxy)]benzene (TCPOBOP) (Maher et al., 2005; Wagner et al., 2005; 
Moffit et al., 2006). More recently, it has been demonstrated in mice that the induction of 
MRP4 is dependent on the transcription factor NF-E2-related factor (Nrf2) (Aleksunes et 
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al., 2007; Maher et al., 2007). Data on the regulation of human MRP4 by xenobiotic 
activated nuclear receptors is however limited. It was demonstrated in HepG2 cells that 
bile acids can induce human PPARá via FXR. Hence, this provides molecular evidence 
for a cross-talk between FXR and PPARá pathways in humans (Pineda Torra et al., 
2003). In addition, it was also reported that CAR activators can increase MRP4 
expression in primary human hepatocytes and HepG2 (Assem et al., 2004). Taken 
together, these findings suggest that human and rodent MRP4 genes may be regulated via 
nuclear receptor mediated mechanisms. Work is still needed to further examine this 
aspect of MRP4 gene regulation. 
 
 
1.5. Nuclear Receptors (NRs) 
The nuclear receptor (NR) superfamily comprises of a number of ligand-dependent and 
ligand-independent transcription factors that play important cellular functions by 
transferring endogenous (e.g. small lipophilic hormones) and exogenous (e.g. drugs, 
xenobiotics and environmental compounds) stimuli into cellular responses by regulating 
the expression of the target genes (Wang and LeCluyse, 2003). The regulation of gene 
expression at transcriptional level has important roles in both cellular functions (e.g. cell 
signaling, developmental processes, metabolism, differentiation and apoptosis) and body 
defensive systems (i.e. phase I and II xenobiotic metabolizing enzymes and transporter 
systems).  In addition, dysfunction of nuclear receptor signaling can result in several 
metabolic disorders such as obesity, cancer, infertility and diabetes (Gronemeyer et al., 
2004). 
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To date, 48 human nuclear receptor genes have been identified. These nuclear receptors 
are broadly categorized into two groups based on their ligand status at the time of their 
discovery. The first group comprises of the classical steroid/hormone receptors including 
glucocorticoid, mineralocorticoid, retinoids, vitamin D3, estrogen, progesterone and 
thyroid hormone receptors. These steroids and hormones are known to play important 
endocrine functions before the genes encoding for their receptors were cloned 
(Mangelsdorf et al., 1995; Chambon, 1996). Members of the second group are referred to 
as orphan nuclear receptors. These represent half of the total number of nuclear receptors 
(24 of the 48 different genes in human) (Benoit et al., 2006). These orphan nuclear 
receptors were identified without prior knowledge of their ligand and defined gene family 
(Giguere et al., 1988), via low stringency screening of cDNA libraries and polymerase 
chain reaction screens with degenerate primers (Blumberg and Evans, 1998) and more 
recently by genome sequence analysis (Robinson-Rechavi and Laudet, 2003). Orphan 
nuclear receptors include the aryl hydrocarbon receptor (AhR), pregnane X receptor 
(PXR), constitutive androstane receptor (CAR), retinoid X receptor (RXR), liver X 
receptor (LXR) and farnesoid X receptor (FXR). 
 
A unifying feature of nuclear receptors is that each of them consists of an assembly of 
independent but interacting functional modules (Moore, J.T. et al., 2006). Each receptor 
generally has three major domains (Figure 1.2). The N-terminal domain contains a 
transactivation domain commonly known as activation function-1 (AF-1) domain. This 
domain varies in length and in sequence in different family members and is recognized 
by co-activators and/or other transcription factors. The central DNA binding domain 
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(DBD), which is about 70 amino acids long, has two C4 type zinc-finger motifs and is the 
most highly conserved sequence segment among nuclear receptors. This DBD links the 
receptor to the specific promoter regions of its target genes, termed hormone response 
elements (HRE) or xenobiotic response elements (XRE). The HRE or XRE is usually 
composed of two hexameric half-sites that can be recognized as inverted, everted or 
direct repeats with a 3- to 6- basepair spacing (Wang and LeCluyse, 2003; Gronemeyer et 
al., 2004). A less conserved multifunctional module, the ligand binding domain (LBD), is 
located at the C-terminal. This domain has an overall well conserved architecture 
between various family members. However, it diverges sufficiently to allow selective 
ligand recognition. This domain also contains dimerization motifs; ligand-induced 
activation domains such as the activation function 2 (AF-2) and sequences that mediate 
nuclear localization of the receptor (Francis et al., 2003; Wang and LeCluyse, 2003; 




Figure 1.2. Schematic illustration of the structural organization of nuclear receptors. 
Members of the nuclear receptor superfamily consist of four modular domains: a highly 
variable N-terminal region that in some receptors harbors an activation function (AF-1),  
a DNA binding domain (DBD) consisting of two zinc-finger motifs, a flexible hinge 




AF-1 DBD Hinge LBD AF-2 N-terminal C-terminal 
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Generally, most unactivated nuclear receptors (e.g. GR and RARá) reside in the 
cytoplasm while some nuclear receptors (e.g. PXR) reside in the cell nucleus. In the 
absence of ligand, the LBD of many nuclear receptors is bound to a set of heat shock 
proteins or transcriptional co-repressors such as RIP140, nuclear receptor co-repressor 
(NcoR) and silencing mediator for retinoid and thyroid hormone receptor (NcoR2/SMRT) 
(Cavailles et al., 1995; Chen and Evans, 1995; Gronemeyer et al., 2004). These co-
repressors inhibit the transcriptional activation function of the nuclear receptors. 
Typically, upon selective ligand binding, nuclear receptors undergo allosteric changes 
that enable the dissociation of co-repressors followed by dimerization and nuclear 
translocation of the activated nuclear receptors. Activated nuclear receptors can function 
as monomers (e.g. steroidogenic factor-1 (SF1)), homodimers (e.g. GR), or heterodimers 
with promiscuous RXR (e.g. RAR, PXR, CAR and several orphan nuclear receptors). In 
many cases, nuclear receptor localizes to the nucleus in the form of homo- or heterodimer. 
Once in the nucleus, ligand-nuclear receptor complexes bind and achieve high affinity 
association with specific response elements within the regulatory region(s) of target 
genes to modulate target genes expression.  The DNA-bound, ligand-activated nuclear 
receptor functions as transcription factor and serves as docking site for co-activators  
(Onate et al., 1995; Whitfield et al., 1999; Moore, J.T. et al., 2006). Binding of a co-
activator protein is believed to be one of the key events in initiating transcriptome 
assembly and subsequent gene transcription (Moore, J.T. et al., 2006). In the following 




1.5.1. Aryl Hydrocarbon Receptor (AhR) 
The AhR is a cytosolic ligandactivated transcription factor that plays important roles in 
xenobiotics biotransformation. AhR belongs to the PAS (Per-ARNT-Sim) family of 
transcription factors which controls the expression of many phase I (e.g. CYP1A1, 
CYP1A2 and CYP1B1) as well as several phase II metabolizing enzymes (e.g. 
glutathione-S-transferases). As no physiological endogenous ligand of AhR has been 
identified (Vrzal et al., 2004), AhR is classified as an orphan nuclear receptor, although 
AhR-dependent responses elicited in the absence of exogenous ligands strongly support 
the existence of such a ligand (Denison et al., 2002; Vrzal et al., 2004). Further, studies 
involving AhR null mice showed retarded growth rate, defective liver and immune 
system development and hepatic retinoid accumulation (Andreola et al., 1997; Mimura 
and Fujii-Kuriyama, 2003), suggesting that AhR is likely to play important physiological 
roles. Exogenous ligands for the AhR include drugs (e.g. â-Napthoflavone (BNF)), 
environmental pollutants (e.g. benzo[a]pyrene (BP), dioxin, halogenated (HAHs) and 
polycyclic aromatic hydrocarbons (PAHs)), as well as naturally-occurring dietary 
chemicals (e.g. flavonoids, carotenoids and phenolics). AhR is also implicated as a 
mediator of chemical carcinogenesis and teratogenesis via the adverse effects of 
metabolic activation of BP and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) 
respectively (Mimura and Fujii-Kuriyama, 2003; Nebert et al., 2004; Vrzal et al., 2004). 
 
In the cytosol, AhR is latent in a multiprotein complex consisting of one AhR, two 
molecular chaperon heat-shock protein 90 (hsp90), a small protein (p23) and an 
immunophilin-like protein termed XAP. Upon ligand binding, AhR dissociates from the 
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chaperon proteins and translocates into the nucleus, where it heterodimerizes with aryl 
hydrocarbon receptor nuclear translocator (ARNT). The heterodimer binds to specific 
DNA sequences termed dioxin or xenobiotic response element (DRE or XRE), which has 
a core sequence of 5-TNGCGTG-3 and activates target gene expressions (Mimura and 
Fujii-Kuriyama, 2003). AhR and ARNT can form homodimers but neither is capable of 
recognizing DREs (Matsushita et al., 1993). 
 
 
1.5.2. Retinoid X Receptor (RXR) 
The physiological effects of retinoic acids (RAs) are mediated by members of two 
families of nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X 
receptors (RXRs). RXRs are encoded by three distinct human genes, namely the RXRá 
(NR2B1), RXRâ (NR2B2) and RXRã (NR2B3) (Mangelsdorf et al., 1990; Mangelsdorf 
et al., 1992). RXRá is predominantly expressed in the liver, kidney, epidermis and 
intestine. Expression of RXRâ is widely distributed and can be detected in almost every 
tissue. While RXRã expression is mostly restricted to the muscle and certain parts of the 
brain as well as the pituitary (Mangelsdorf et al., 1992; Dolle et al., 1994). The search for 
natural RXR ligand led to the discovery of 9-cis retinoic acid (9cRA) as a high affinity 
ligand for all three RXRs. Although the biosynthesis and the presence of 9cRA have been 
reported in developing embryos, 9cRA has not been clearly detected in mammalian cells. 
Therefore it cannot be concluded that 9cRA is the actual natural ligand for RXRs (Mertz 
et al., 1997). Thus, the search is still on to determine the endogenous ligand for RXRs. 
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All three RXR subtypes are common heterodimerization partners for members of the 
subfamily 1 nuclear receptors, including RAR, PXR and CAR. Both in vitro and in vivo 
studies have showed that all these nuclear receptors require RXR as a heterodimerization 
partner for their function and in most cases, the RXR partner may be any one of the three 
RXR subtypes (Germain et al., 2006b). RXR-RAR heterodimers bind to a direct repeat of 
the AGGTCA core motif with a 5 bp spacing (DR-5) and DR-2, while RXR-CAR and 
RXR-LXR bind to DR-4, RXR-VDR and RXR-PXR to DR-3, and RXR-PPAR to DR-1 
(Germain et al., 2006b) (Figure 1.3). The spacing is the determinant for the binding 
specificity. Nevertheless, the sequence of the core motif, the sequence of spacer or that of 
the flanking region can also be important. RXRs can form homodimers in vitro however 






Figure 1.3. Schematic illustration of DNA binding of nuclear receptors. 
The xenobiotic-sensing nuclear receptors bind as heterodimers with the RXR to repeats 
of the nucleotide hexamer AG(G/T)TCA with variable spacing. The hexamers can be 
arranged either as direct repeats (DR), everted repeats (ER) or inverted repeats (IR).  
 
 
1.5.3. Retinoic Acid Receptor (RAR) 
The retinoid acid receptors (RARs) are members of the nuclear receptor 1B subfamily 
(NR1B). These receptors mediate the pleiotropic effects of retinoids regulating a wide 
variety of essential biological processes such as vertebrate embryonic morphogenesis, 
organogenesis, cell growth arrest, differentiation, apoptosis and homeostasis. (Sporn et 
al., 1976; Chambon, 2005). There are three RAR subtypes namely the RARá (NR1B1), 
RARâ (NR1B2) and RARã (NR1B3) that are encoded by three distinct genes (Giguere et 
Target Gene 
DBD DBD 
AGGTCA AGGTCA (N)X 
LBD LBD 
xenosensor RXR 





al., 1987; Petkovich et al., 1987). RARá is present in most tissues while both RARâ and 
RARã expressions are more selective (Dolle et al., 1990). These differences in tissue 
distribution suggest that RARs have distinct physiological functions. Natural retinoids are 
produced in vivo from the oxidation of vitamin A and all-trans-retinoic acid (ATRA), 
being the most potent biological active metabolite of vitamin A, is a natural ligand for 
RARs. Unlike classical steroid hormone receptors, RARs function as heterodimers with 
either one of the three retinoid X receptors (RXRá, RXRâ or RXRã). RXR-RAR 
heterodimers bind direct repeats of polymorphic arrangements of canonical motif 5-
PuG(G/T)TCA separated by five (DR5) or two (DR2) nucleotides (Glass and Rosenfeld, 
2000; Germain et al., 2006a) (Figure 1.3). Aberrant retinoid signaling mechanisms have 
been linked to cancer and hyperproliferative diseases. The most direct implication of 
RAR in human disease is found in acute promyelocytic leukemia (APL), characterized by 
a block to normal granulocytic differentiation which, if untreated, results in the lethal 
accumulation of immature promyelocytes. This disease is caused by a reciprocal 
chromosomal translocation between RARá and promyelocyte leukemia protein (PML) 
leading to alterations of both the RARá and PML signaling pathways (de The et al., 
1990). Fortunately, retinoid anti-cancer activity can be demonstrated through the use of 
supraphysiological doses of ATRA in the treatment of APL. 
 
1.5.4. Pregnane X Receptor (PXR) 
Pregnane X receptor (PXR) was first characterized as xenosensing transcription factors 
regulating the induction of phase I and II xenobiotic-metabolizing enzymes as well as 
transporters in response to exogenous stimuli. The human PXR (NR1I2) together with its 
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homologs in rat, rabbit, pig, monkey and dog were identified in 1998. Studies have 
shown that all PXRs (mouse, human, rat and rabbit) expression are predominantly 
expressed in the liver and intestine, and to a small extent in the kidney and lungs (Wang 
and LeCluyse, 2003). PXR is found exclusively in the nucleus and a direct correlation 
between ligand binding and receptor activation, without the need of nuclear translocation 
has been demonstrated (Handschin and Meyer, 2003). The well known exogenous 
agonists of PXR include pharmaceutical drugs (e.g. RU486 and rifampicin) and synthetic 
steroids (e.g. PCN) (Willson and Kliewer, 2002). Natural endogenous ligands of PXR 
include bile acids (e.g. lithocholic acid) and pregnanes. PXR must be activated by 
cognate ligands and heterodimerize with RXR. Subsequently, RXR-PXR heterodimers 
binds to the DR-3 elements found in the regulatory regions of target genes (Figure 1.3). 
Although PXR is commonly associated with the regulation of CYP3A genes (phase I 
drug metabolizing enzymes), it is also able to regulate other aspects of drug metabolism 
(i.e. phase II) and excretion (i.e. phase III). PXR also regulate the expression of phase II 
enzymes (e.g. glutathione S-transferase (GST) and sulfotransferase (SULT)) and organic 
anion transporters such as BSEP, NTCP, OATP2, MRP3 and MDR2. The coordinated 
regulation by PXR of the uptake of xenobiotics and the subsequent metabolism by Phases 
I and II enzymes as well as the efflux of the metabolites into the bodys excretory 
pathways suggest that PXR serves as a master regulator of hepatic drug disposition (Tien 





1.5.5. Constitutively Activated / Androstane Receptor (CAR) 
In 1994, the orphan nuclear receptor CAR (NR1I3) was isolated through screening of a 
cDNA library using a probe directed towards a conserved motif in the DNA-binding 
domain (Baes et al., 1994). Like PXR, CAR dimerizes with RXR and is abundantly 
expressed in the liver and intestine. CAR was initially described as constitutively active 
and hence the name (Baes et al., 1994). It is reported that RXR-CAR binds to 
phenobarbital responsive enhancer module (PBREM) to induce transcription of members 
of the CYP2B family of enzymes (Baes et al., 1994) as well as organic anion transporters 
such as BSEP, NTCP, OATP2, MRP3 and MDR2 (Staudinger et al., 2003). Analysis of 
PBREM and other CAR regulated promoters revealed that CAR preferentially binds DR-
4 binding sites (Tien and Negishi, 2006) (Figure 1.3). In transient transfection and in 
stably transfected HepG2 cells, CAR transactivated and triggered high basal activity of 
target reporter genes regulated by the mouse CYP2B10 and the human CYP2B6 PBREM, 
in the absence of exogenous ligands (Sueyoshi et al., 1999). This is consistent with the 
initial reports describing CAR as the constitutively activated receptor. 
 
By screening small hydrophobic compounds, two naturally occurring androstane 
metabolites, androstanol (5á-androstan-3á-ol) and androstenol (5á-androstan-16-en-3á-ol) 
were identified as putative endogenous ligands. However, instead of activating CAR, 
both ligands act as antagonists by dissociating CAR from its co-activator and inhibiting 
the transactivation of CAR (Willson and Kliewer, 2002; Wang and LeCluyse, 2003). 
Both androstanol and androstenol blocks CAR constitutive activity only at high 
concentrations (micromolar) that are far above those reached in vivo. To date, there are 
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no known endogenous agonists that can directly activate CAR in physiological pathways. 
The anti-seizure drugs phenobarbital (PB) and phenytoin are the most well-known 
exogenous activators of CAR. Xenobiotics such as 1, 4-bis[2-(3, 5-
dicholoropyriyloxy)]benzene (TCPOBOP) and 6-(4-chlorophenyl)imidazo[2, 1-b][1, 3] 
thiazole-5-carbaldehyde 0-(3, 4-dichlorobenzyl)oxime (CITCO) have also been shown to 
activate mouse and human CAR respectively (Tzameli et al., 2000; Tien and Negishi, 
2006). 
 
It had been reported that CAR can be indirectly activated by high concentrations of both 
bile acids and bilirubin. Both of these pathways result in detoxification and induced 
clearance of these endogenous toxins. Since normal physiological concentrations of these 
endobiotics cannot effectively activate the CAR and PXR, these receptors are referred to 
as sensors, most probably to monitor a given physiological status of the organism (for 
example, the amount of fatty acids or cholesterol) to finely tune homeostasis and to 
protect against the consequences of pathologically elevated levels (Gronemeyer et al., 
2004; Moore, D.D. et al., 2006).  
 
1.5.6. Glucocorticoid Receptor (GR) 
The glucocorticoid receptor (GR), being one of the earliest receptors cloned in the mid 
80s, is a classic member of the nuclear receptor subfamily 3C (Hollenberg et al., 1985). 
Individually or with other receptors, GR plays pivotal roles in physiological functions 
such as stress response, metabolism, immune function, growth, development and 
reproduction. GR share structural similarities with other receptors, containing the N-
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terminal transactivation domain together with DNA binding domain and the c-terminal 
ligand binding domain. A hinge region links the DBD and the LBD (Figure 1.2) 
(Mangelsdorf et al., 1995). Overall sequence identities for GR among different species 
(human, rat and mouse) are between 81% and 97% (Whitfield et al., 1999). Unliganded 
GR exists as a complex with heat shock proteins in the cytoplasm. Upon binding to its 
endogenous ligand cortisol, GR dissociates from the cytoplasmic complex, translocates to 
the nucleus and forms a homodimer followed by binding specifically to its target DNA 
sequence, termed glucocorticoid-response elements (GREs) via DBD. Classic GREs 
consist of two hexameric (i.e. AGAACA) inverted repeat halfsites separated by a 3-bp 
spacer.  
 
GR is expressed in almost all tissues although tissue-specific and cell cycle-specific 
regulation of GR levels have been reported (Lu et al., 2006). In humans, the natural 
ligand for GR is cortisol, also called hydrocortisone. It is the major glucocorticoid in 
human exerting a vast array of physiological functions via GR. In contrast, the major 
glucocorticoid in rodents is corticosterone. Synthetic glucocorticoids used in the medical 
community such as dexamethasone and prednisolone are common exogenous agonists for 
GR while RU-486 is a potent GR antagonist. 
 
 
1.6. Role of Nuclear Receptors in the Regulation of Xenobiotic 
Metabolizing Enzymes (XMEs) and Transporters 
 
Living organisms have derived a system to deal with potentially toxic compounds and 
prevent their accumulation. Two general mechanisms that have evolved for drug 
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metabolism are biotransformation and transport. Enzymes involved in biotransformation 
reactions are categorizes into two groups  phase I and phase II enzymes. Phase I 
reactions expose or introduce a polar group onto target molecules leading to the 
inactivation of most drugs. However, in some cases, metabolic transformation of 
xenobiotics can result in active or toxic metabolites (Handschin and Meyer, 2003). Phase 
I enzymes include the cytochrome P450 (CYP) superfamily of enzymes, mono-
oxygenases, amidases and esterases. While phase I reactions add reactive groups to the 
xenobiotics, phase II enzymes are mainly involved in the conjugation of either the parent 
drug or the phase I metabolites resulting in more polar molecules which can be easily 
eliminated. Major phase II enzymes include UDP-glucuronosyl transferase (UGT), 
sulfotransferase (SULT) and glutathione S-transferase (GST) enzymes (Wang and 
LeCluyse, 2003). Finally, the intracellular levels of both parent drugs and their 
metabolites are excreted by transporter proteins, localized on the sinusoidal and the apical 
membrane of hepatocytes, intestine and kidney (Handschin and Meyer, 2003).  
 
In recent years, numerous studies have demonstrated the roles of nuclear receptors in the 
regulation of phase I and phase II drug metabolizing enzymes as well as phase III efflux. 
Some of the more well-studied nuclear receptors include AhR, PXR, and RAR. In early 
studies, it was reported that pregnenolone 16á-carbonitrile (PCN) and phenobarbital (PB) 
are two prototypical inducers of phase I enzymes. PCN was reported to induce CYP3A 
genes while PB was reported to induce CYP2B family via PXR and CAR respectively. 
Both were reported for their ability to increase hydroxylase activity in the liver and 
confer resistance to various xenobiotics in rodents (Selye, 1971; Waxman and Azaroff, 
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1992). It has also now been shown that other phase I enzymes such as CYP1A1, 
CYP1A2 and CYP1B1 are transcriptionally regulated by AhR/ARNT heterodimers in 
response to dioxin, polycyclic aromatic hydrocarbons (PAHs) such as 3-
methylcholanthrene (3-MC) and polyhalogenated aromatic hydrocarbons (Nebert et al., 
2004). In addition, activated RAR has also been shown to up-regulate the expression of 
CYP26 (Bastien and Rochette-Egly, 2004).  
 
Several lines of evidence have also revealed that nuclear receptors can modulate the 
expression of phase II enzymes as well as phase III transporters. For instance, 
AhR/ARNT heterodimers were shown to up-regulate phase II enzymes such as GST and 
UGT (Mimura and Fujii-Kuriyama, 2003). PXR and CAR were shown to up-regulate 
UGT, SULT and GST (Xu et al., 2005; Zhou et al., 2005). In addition, many studies 
using rodent models had shown that CAR and PXR can up-regulate the expression of 
phase III transporters such as P-gp and MRPs (Synold et al., 2001; Teng et al., 2003; 
Klaassen and Slitt, 2005). Besides PXR and CAR, AhR was also demonstrated to induce 
MRP2, MRP3, MRP5 and MRP6 expression in mouse liver (Maher et al., 2005). In vivo 
studies in mice had revealed that several murine homologs, including MRP4, can be 
transcriptionally regulated by nuclear receptors (Kast et al., 2002; Assem et al., 2004; 
Maher et al., 2005; Moffit et al., 2006).  
 
In conclusion, these gene regulation studies clearly suggested that nuclear receptors 
played pivotal roles as xenosensors in the transcriptional regulation of an array of XMEs 
and transporters, which are essential for metabolism and excretion of xenobiotics.  
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1.7. Aims, Study Approach and Significance 
In recent years, MRPs have gained importance in the medical community because they 
have been implicated in the clinically observed multidrug resistant phenotype in the 
treatment of cancers and viral infections. Numerous studies have been focused on various 
MRP members to characterize their structures, substrate profiles, functions, expression 
and their regulation. The regulation of MRPs by xenobiotics is of particular interest 
because of their potential roles in transport of therapeutic agents and in multidrug 
resistance.  
 
As noted in Section 1.6, nuclear receptors play important roles in the regulation of drug 
metabolizing enzymes as well as transporters. Most of the studies on the regulation of 
MRPs were performed in rodent models. Little data exists on the induction of MRP4 in 
humans. It is also worth noting that the species specific regulation of the same 
enzyme/transporter resulting from the divergence of the xenobiotic receptor ligand 
binding domains means that such drug-drug interactions relevant to humans cannot be 
reliably studied in standard rodent models. Hence in order to identify the actual 
regulation of human proteins, one has to use lines of humanized rodents expressing the 
human receptors and/or transporters instead of their wild-type rodent counterparts. A 
cheaper and more robust alternative is to use human liver cell lines such as HepG2 and 
Huh7 cells. The use of human cell lines in this study allows easy manipulation and the 
application of transient transfection to facilitate the elucidation of how the human MRP4 
(hMRP4) can be regulated by nuclear receptors. This will provide insight of how the 
hMRP4 may be regulated in vivo. Hence this study aims to investigate the role of 
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activated nuclear receptors in the transcriptional regulation of hMRP4 in human liver cell 
lines.  
 
In this study design, the 2kb hMRP4 promoter sequence was first isolated from HepG2 
cells. The sequence of this 2kb hMRP4 promoter sequence was then analyzed by 
MatInspector software analysis to identify putative nuclear receptor response elements 
within the promoter. Based on these predictions, a series of truncated promoter constructs 
were generated via PCR and cloned into pGL3 luciferase reporter plasmid. These 
truncated promoter constructs were generated to systematically exclude certain putative 
response elements so as to assess their contribution to hMRP4 promoter activity in the 
truncation studies. Subsequently, these promoter reporter plasmids were co-transfected 
into HepG2 and/or Huh7 cells with pcDNA6/â-galactosidase expression plasmid as the 
transfection control. The transient transfection studies were carried out progressively in 5 
stages. The first stage involved the screening of nuclear receptor agonists/activators to 
identify those that showed ability to induce hMRP4 promoter activity. The second stage 
involved dose dependent studies to determine the optimum concentration that induce the 
highest hMRP4 promoter activity. The third stage was the analysis of truncated promoter 
constructs to assess their transcriptional responsiveness to nuclear receptor agonists. The 
fourth stage was the nuclear receptor over-expression studies to establish the dependency 
of the observed promoter activation on the intracellular concentrations of the nuclear 
receptor. Finally, transient transfection of wild-type and site directed mutated promoter 
constructs served to further verify the role of nuclear receptors in the regulation of 
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hMRP4 promoter activity. The experimental design of hMRP4 promoter analysis is 
illustrated in Figure 1.4. 
 
 
Figure 1.4. Study approach for the transcriptional regulation of hMRP4 gene. 
After the cloning and sequencing of the ~2kb hMRP4 promoter region, software analysis was 
done on the promoter sequence to predict putative nuclear receptor response elements. Based 
on these predictions, a series of truncated hMRP4 promoter constructs were generated 
systematically by PCR and cloned individually into pGL3 reporter plasmids. Subsequently, 
transient transfection using these promoter constructs were conducted in five different stages, 
namely the screening of xenobiotics, dose-dependent studies, truncated studies, over-
expression studies and mutant promoter studies. For each of these studies, cell lysates were 
assayed for luciferase activity, which was normalized to â-galactosidase activity, and 
expressed as relative luciferase activity (RLU). RLUs of treated samples were compared to 
appropriate negative control for each experiment to obtain fold induction. Fold induction is 
used as a measure for hMRP4 promoter induction. 
Cloning of ~2kb hMRP4 promoter region   
Software Analysis 
Prediction of putative nuclear receptor response elements 
Generation of truncated hMRP4 promoter constructs 
By PCR and cloning into pGL3 reporter plasmids 
Transient transfection studies 
















Determination of Fold Induction 
Luciferase activity was normalized to â-galactosidase activity to obtain RLUs. RLUs of treated 
samples were compared to appropriate negative control to obtain fold induction. 
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2. Materials and Methods  
2.1. Chemicals and Plasmids 
All cell culture chemicals were purchased from Life Technologies (Carlsbad, CA, U.S.A.) 
except L-glutamine and penicillin/streptomycin which were obtained from Sigma-Aldrich 
(St. Louis, MO, U.S.A.). LIPOFECTAMINE and OPTI-MEM I reduced serum 
medium were also purchased from Life Technologies. Escherichia coli (E. coli) DH5á, 
pcDNA6/V5-His/lacZ plasmid, pcDNA6A expression vector and Purelink HiPure 
Plasmid Midiprep Kit were purchased from Invitrogen (Carlsbad, CA, U.S.A.). In 
addition, the pGEM-T cloning vector and pGL3-basic luciferase reporter vector, 
luciferase and â-galactosidase enzyme assay systems, access RT-PCR kit, reverse 
transcription system kit and CellTiter 96® AQueous one solution cell proliferation assay 
were obtained from Promega (Madison, WI, U.S.A.). QIAquick Gel Extraction kit and 
RNeasy Mini kit were purchased from QIAGEN (Valencia, CA, U.S.A.). Quikchange® 
Site-Directed Mutagenesis kit was purchased from Stratagene (La Jolla, CA, U.S.A.). All 
primers were purchased from Sigma-Proligo (St. Louis, MO, U.S.A.). All molecular 
biology reagents were obtained from New England Biolabs (Beverly, MA, U.S.A.). All 
other chemicals and xenobiotics were obtained from Sigma-Aldrich (St. Louis, MO, 
U.S.A.). PXR (NM_003889.2) cDNA clone was purchased from OriGene Technologies 
(Rockville, U.S.A), while AhR (BC070080), ARNT (BC060838), RARá (BC008727) 
and RXRá (BC110998) cDNA clones were bought from American Type Culture 




2.2. Cell Lines and Cell Culture 
The human hepatocellular carcinoma cell line HepG2, was purchased from American 
Type Culture Collection (ATCC), (Manassas, VA, U.S.A.). The human hepatoma cell 
line Huh7, was purchased from RIKEN Bioresource Center (Japan). HepG2 and Huh7 
cells were routinely cultured in complete medium consisting of Dulbeccos modified 
eagle medium (DMEM), 1mM sodium pyruvate, 2mM L-glutamine, 0.1mM non-
essential amino acids, 100units/ml penicillin, 100ìg/ml streptomycin and 10% fetal 
bovine serum (FBS). All cells were grown at 37oC in a humidified atmosphere of 95% air 
and 5% CO2. 
 
2.3. 5 Rapid Amplification of cDNA Ends (5 RACE) 
5 RACE was previously performed in the laboratory by Miss Tan Weiqi to identify the 
transcriptional start site of the human MRP4 gene. This allows the cloning of the 
promoter region upstream of the 5 untranslated region of the hMRP4 gene.  
   
2.4. Cloning of hMRP4 Promoter 
Based on the 5 RACE, the transcriptional start site of the hMRP4 gene was determined 
to be at position -43 with respect to translational start site (+1). A 1981 bp (~2kb) 5-
flanking promoter region (named as M4A) of the hMRP4 gene, which is found on 
chromosome 13 (GenBank accession number NT_009952; appendix) was cloned into 
pGEM-T vector. This was achieved by PCR amplification in a 50ul reaction volume, 
using DyNAzyme EXTTM DNA polymerase (Finnzymes, Espoo, Finland), 500ng HepG2 
genomic DNA as template with M4A/KpnI/For (5  
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AACGGTACCGATTATGGGCTTGTACAG  3) and MRP4/SacI/Rev (5  
GTTGAGCTCTCCGAAATTCACTATCCGAG  3) as primers. The underlined 
palindromic sequences in the primers denote KpnI and SacI restriction endonuclease 
recognition sites respectively. PCR was performed with initial denaturing step at 94oC for 
3mins, followed by 40 cycles of denaturation at 94oC for 30sec, annealing at 58oC for 
30sec and extension at 72oC for 2mins. A final extension step at 72oC was carried out for 
5mins. The amplicons (M4A promoter construct) was cloned into pGEM-T via TA 
cloning according to the suppliers instructions. Subsequently, M4A was extracted via 
KpnI & SacI restriction digest, purified and subcloned into pGL3-basic luciferase 
reporter vector to produce M4A-pGL3. M4A-pGL3 was transformed into E. coli DH5á 
and extracted using Purelink  HiPure Plasmid Midiprep Kit for subsequent transfection 
experiments. M4A promoter sequence was verified by restriction digest and sequencing. 
 
2.5. Prediction of Putative Nuclear Receptor Response Elements 
Analysis of the ~2kb M4A promoter region for putative nuclear receptor binding sites 
was performed with the web-based MatInspector software (Genomatix, Munich, 
Germany). MatInspector can be assessed from 
http://www.genomatix.de/matinspector.html. The search algorithm for MatInspector was 
described by (Quandt et al., 1995). The M4A promoter was first analyzed using default 
configurations of the program. User defined sequences were then manually inputted into 
MatInspector to identified additional nuclear receptor response elements (Pascussi et al., 
2003; Schoneveld et al., 2004; Sun et al., 2004). 
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2.6. Cloning of hMRP4 Truncated Promoter Constructs 
Based on the locations of predicted putative nuclear receptor response elements, several 
other hMRP4 truncated promoter constructs were subsequently generated by PCR (as 
described in Section 2.4) using M4A-pGEM-T as template, together with M4B/KpnI/For 
(5  CGGGGTACCAAATGACTGAAGACTTAGAG  3), M4C/KpnI/For (5  
CGGGGTACCATTTTGATTTTTGCATCTCT  3), M4D/KpnI/For (5  
CGGGGTACCTTTCCTCTTATATTCCTTTC  3) or M4E/KpnI/For (5  
TTAGGTACCACGACAGCATTCATCCATCT  3) as forward primer and 
MRP4/SacI/Rev (5  GTTGAGCTCTCCGAAATTCACTATCCGAG  3) as the 
reverse primer. The resulting PCR fragments were then cloned into pGEM-T vector via 
TA cloning. All truncated hMRP4 promoter constructs-pGEM-T plasmids (i.e. M4B-
pGEMT-T to M4E-pGEM-T) were extracted using Purelink HiPure Plasmid Midiprep 
Kit followed by restriction digestion using KpnI and SacI. The digested fragments were 
subjected to gel electrophoresis on a 1.2% w/v agarose gel and subsequently purified 
using QIAquick Gel Extraction kit. Following gel purification, the fragments were ligated 
into pGL3-basic luciferase reporter vector via KpnI and SacI restriction sites. The 
sequences of all the truncated promoter constructs were verified by restriction digest and 
sequencing. 
 
2.7. Cloning of Nuclear Receptor cDNA into pcDNA6A Expression 
Plasmid 
 
RXRá cDNA was available in pCMV-SPORT6 expression vector while PXR cDNA was 
available in pCMV6-XL4 expression vector. Hence, RXRá and PXR expression clones 
were purchased directly from their distributors. PXR-pCMV6-XL4 and RXRá-pCMV-
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SPORT6 plasmid DNA were prepared using Purelink HiPure Plasmid Midiprep Kit for 
subsequent nuclear receptor over-expression studies. RARá cDNA was available in 
pOTB7 cloning vector while AhR and ARNT cDNA were available in pBluescriptR 
cloning vector. The open reading frame (ORF) of RARá, AhR and ARNT were amplified 
using designed primers listed in Table 2.1. The respective amplicons were cloned into 
pGEM-T vector according to the suppliers instructions. The ORF of each nuclear 
receptor was extracted using HindIII and XhoI restriction digest, purified and cloned into 
pcDNA6A expression vector. RARá-pcDNA6A, AhR-pcDNA6A and ARNT-pcDNA6A 
plasmid DNA were prepared using Purelink HiPure Plasmid Midiprep Kit for 
subsequent nuclear receptor over-expression studies. 
 
Table 2.1. Primers used to amplify open reading frame of nuclear receptors. 
The underlined nucleotides denote unique palindromic sequences recognized by 
respective restriction enzymes. For and Rev represent forward and reverse primers 
respectively. 
Primer Sequences Annealing Tm (oC) 
RARá ORF HindIII 
For 5-TTAAAGCTTATGGCCAGCAACAGCAGCTC-3 70
oC 
RARá ORF XhoI 
Rev 5-TTTCTCGAGTCACGGGGAGTGGGTG-3 70
oC 
AhR ORF HindIII 
For 5-TTAAAGCTTCGTCGGCTGGGCACCATGAA-3 68
oC 
AhR ORF XhoI 
Rev 5-GACCTCGAGATTGGGCTTGGAATTACAGG-3 68
oC 
ARNT ORF HindIII 
For 5-TTAAAGCTTCATCTGCGGCCATGGCG-3 66
oC 




2.8. Isolation of Total RNA and RT-PCR of Nuclear Receptor 
Transcripts in Cell Lines 
 
Total RNA was extracted from HepG2 and Huh7 cells using the RNeasy Mini kit 
according to the manufacturers protocol. The expression levels of each nuclear receptor 
were measured using Reverse Transcription together with PCR amplification (RT-PCR). 
This was carried out on the total RNA extracts using Access RT-PCR Kit. The sequences 
and annealing temperatures (Tm) of the primers and their expected amplicon lengths are 
listed in Table 2.2. In each RT-PCR reaction, AMV/Tfl reaction buffer (1X), dNTP mix 
(0.2mM), downstream and upstream primers (1ìM each), magnesium sulphate (1mM), 
AMV reverse transcriptase and Tfl DNA polymerase (0.1U/ìl each), and 0.5ìg of RNA 
were assembled according to the manufacturers protocol, to a final reaction volume of 
50ìl. Reverse transcription was carried out at 48oC for 45min followed by a denaturing 
step at 94oC for 2min. The first strand cDNA obtained from reverse transcription was 
subjected directly to 30 cycles of PCR amplification. Each PCR cycle comprises of 
denaturation at 94oC for 1min, annealing at primer-specific annealing Tm (Table 2.2) for 
30sec and extension at 68oC for 45sec. After 30 cycles, a final extension step was carried 









Table 2.2. List of primers used for RT-PCR 
The sequences and annealing temperatures (Tm) of each set of primers used for RT-PCR 
and the expected lengths of the RT-PCR products of each nuclear receptor transcripts are 
indicated. 
Target 






â-actin Forward 5  GATGATGATATCGCCGCGCT - 3 351 55oC 
 
Reverse 5- CTTCTCGCGGTTGGCCTTGG  3 
AhR Forward 5- GTGACTTGTACAGCATAATG  3 316 55oC 
 
Reverse 5- ATCTTCTGACACAGCTGTTG  3 
ARNT Forward 5  GAATTGGACATGGTACCAGG  3 
325 68oC 
 
Reverse 5  AAGCTGATGGCTGGACAATG  3 
RARá Forward 5- CTGCCAGTACTGCCGACTGC  3 234 60oC 
 
Reverse 5  CGTTGTTCTGAGCTGTTGTTCGTA  3 
RARâ Forward 5 - CCAGGAATCGATGCCAATAC  3 247 58oC 
 
Reverse 5 - GACTCGATGGTCAGCACTG  3 
RARã Forward 5 - CAGTACTGCCGGCTACAGAA  3 223 60oC 
 
Reverse 5  TCTGCACTGGAGTTCGTGGTATACT  3 
RXRá Forward 5  CCTTTCTCGGTCATCAGCTC  3 270 55oC 
 
Reverse 5  CTCGCAGCTGTACACTCCAT  3 
PXR Forward 5  AGAAGGAGATGATCATGTCCGA   3 359 56oC 
 
Reverse 5   GTTTGTAGTTCCAGACACTGCC  3 
CAR Forward 5- CCAGCTCATCTGTTCATCCA  3 
626 63oC 
 
Reverse 5  GGTAACTCCAGGTCGGTCTG  3 
GRá Forward 5- CTTACTGCTTCTCTCTTCAGTTCCT  3 204 55oC 
 
Reverse 5- GCAATAGTTAAGGAGATTTTCAACC  3 
GRâ Forward 5- AAAGCACATCTCACACATTA  3 797 60oC 
 




2.9. Detection of Amplified RT-PCR Products 
The RT-PCR products were separated using agarose gel electrophoresis. Ten microlitre 
of each reaction mixture were subjected to gel electrophoresis at 100 volts for 50mins on 
a 1.2% (w/v) agarose gel constituted in Tris-acetate-EDTA (TAE) buffer (40mM Tris-
acetate, 1mM EDTA) and stained with 0.005% (v/v) ethidium bromide. The gels were 
then exposed to UV light to visualize the amplified RT-PCR products. 
 
2.10. CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(MTS Assay) 
 
In this study, ligands (xenobiotics) of various nuclear receptors were used to elucidate the 
roles of nuclear receptors on the regulation of hMRP4 gene expression. The nuclear 
receptors and their ligands were listed in Table 2.3. 
 
Cell viability following xenobiotic treatments was determined using CellTiter 96® 
AQueous One Solution Cell Proliferation Assay. HepG2 or Huh7 cells were seeded into 
96-well plates at a density of 5 x 103 cells per 100ìl per well and then incubated at 37oC 
with 5% CO2. After 24 hrs, the cells were then treated with DMEM containing 1ìM and 
10ìM of various xenobiotics and 100ìM and 1000ìM of PB. These concentrations used 
represented the highest concentrations that would be used for downstream transfection 
experiments. All xenobiotics were dissolved in dimethyl sulphoxide (DMSO) and the 
final concentration of DMSO used does not exceed 0.1% (v/v).  Following 48 hrs of 
xenobiotic treatment, 10ìl of MTS tetrazolium reagent was added to each well and 
incubated at 37oC in a humidified atmosphere of 95% air and 5% CO2 for 1 hour. The 
color changes in each well were then measured at 490nm. 
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Table 2.3. List of nuclear receptors and their ligands 
Nuclear Receptors Ligands / Xenobiotics / Activators / Agonists 
Aryl Hydrocarbon Receptor (AhR) Â-Napthoflavone (BNF) 
3-Methylcholanthrene (3MC) 
Retinoic Acid Receptor (RAR) All Trans Retinoic Acid (ATRA) 
13-cis Retinoic Acid (13cRA) 
Retinoic X Receptor (RXR) 9-cis Retinoic Acid (9cRA) 





Constitutive Androstane Receptor 
(CAR) 
Phenobarbital (PB) 
Diallyl Sulphide (DAS) 




2.11. Transient Transfection 
Twenty four hours before transfection, HepG2 or Huh7 cells were seeded into six-well 
plates at a density of 5.0 x 105 cells / 2ml / well. The LIPOFECTAMINE  reagent was 
used to transfect the DNA plasmids into both cell lines according to the manufacturers 
instruction. For HepG2 cells, 1ìg of promoter-pGL3 reporter plasmid was co-transfected 
with 0.3ìg of pcDNA6/LacZ plasmid into each well. While for Huh7 cells, 0.7ìg of 
promoter-pGL3 reporter plasmid was co-transfected with 0.1ìg of pcDNA6/LacZ 
plasmid into each well. The promoterless-pGL3 reporter plasmid serves as the negative 
control and the pcDNA6/LacZ plasmid expressing â-galactosidase serves as the internal 
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transfection control. DNA plasmids together with LIPOFECTAMINE reagent (6ìl per 
microgram DNA plasmid used) were dissolved in 200ìl of Opti-MEM I reduced serum 
medium. The resultant transfection mixture was incubated at room temperature for 
45mins for the DNA-liposome complexes to form. During the 45mins incubation, 
DMEM from each well were removed and the cells were washed with 1ml of Opti-MEM 
medium. Following washing, 800ìl of Opti-MEM medium was added to each well. After 
the 45mins incubation, 200ìl of the DNA-Liposome transfection mixture was added into 
each well. The cells were then incubated at 37oC for 4hrs in an atmosphere of 95% air 
and 5% CO2. After 4hrs of transfection, 2ml of DMEM with 10% FBS was added to each 
well to stop the transfection process and the cells were incubated overnight at 37oC in an 
atmosphere of 95% air and 5% CO2.  
 
Xenobiotic treatments were carried out 24hrs post-transfection. Appropriate amount of 
various xenobiotics were weighed out and dissolved in DMSO. The dissolved xenobiotics 
were then constituted in DMEM (10% FBS) to the final desired concentrations ranging 
from 0.001ìM to 10ìM. DMSO constituted in DMEM (10% FBS) at a final 
concentration not exceeding 0.1% (v/v) serves as a vehicle control. The cells were 
incubated in DMEM containing DMSO (vehicle control) or test xenobiotic for 48hrs. 
After 48 hrs of xenobiotic treatment (72hrs post-transfection), medium containing the 
xenobiotic was removed and the cells were washed with 2ml of 1 x PBS. This is followed 
by the addition of 300ìl of the freshly prepared 1x reporter lysis buffer (RLB) to each 
well and incubation at 4oC for 15mins. The cells were then scraped off the wells using 
 45
cell scrapers. The resulting cell lysates were then collected into clean 1.5ml eppendorf 
tubes before storage at -80oC.  
 
2.12. Nuclear Receptor Over-Expression Study 
In nuclear receptor over-expression study, Huh7 cells were seeded into six-well plates at 
a density of 5.0 x 105 cells / 2ml / well and incubated at 37oC for 24hrs in an atmosphere 
of 95% air and 5% CO2. Subsequently, nuclear receptor expression plasmids and 
promoter-pGL3 reporter plasmid and pcDNA6/LacZ plasmids were transfected into 
Huh7 cells in two phases sequentially. In the first phase of transfection, 0.5ìg of each 
nuclear receptor expression plasmids or empty expression plasmids were transfected into 
the cells of each well and incubated for 4 hrs. After 4hrs of incubation, the first 
transfection mixture was removed and immediately followed by second phase of 
transfection. In the second phase, 0.7ìg of promoter-pGL3 reporter plasmid was co-
transfected with 0.1ìg of pcDNA6/LacZ plasmid into each well and incubated for 
another 4hrs. The LIPOFECTAMINE  reagent was used to transfect all DNA plasmids 
into the cells according to the manufacturers instruction. The DNA-Liposome 
transfection mixture and DMEM containing xenobiotics were prepared as described in 
Section 2.11. After the two phases of transfection, the cells were immediately treated 
with DMEM (10% FBS) containing appropriate concentration of DMSO or test 
xenobiotics for 48hrs. At the end of the 48h-treatment, cell lysates were harvested as 




2.13. Reporter Gene Expression Assays 
The frozen cell lysates were thawed as one cycle of freeze-thaw is necessary for complete 
cell lysis. The cell lysates were then centrifuged at 13000g at 4oC for 15min to pellet the 
cell debris and the resultant clear supernatant were assayed for both luciferase and â-
galactosidase activities using the luciferase and the â-galactosidase enzyme assay systems 
respectively. Luciferase activities were normalized to the respective â-galactosidase 
activities from the same well and expressed in arbitrary relative luciferase units (RLUs). 
The promoterless pGL3 vector or the DMSO treated samples was used as the negative 
control. RLUs of promoter-pGL3 reporter plasmids were all normalized to RLU of 
promoterless pGL3 vector or DMSO treated samples to obtain fold induction. 
 
2.14. Effects of Xenobiotics on the Expression Levels of Endogenous 
hMRP4 Transcripts 
 
HepG2 and Huh7 cells were seeded into T-25cm2 culture flasks at a cell density of 1.25 x 
106 cells per flask. The cells were incubated at 37oC in an atmosphere of 95% air and 5% 
CO2 for 24hrs. Xenobiotic treatments were carried out 24hrs post-seeding. DMEM (10% 
FBS) containing xenobiotics were prepared as described in Section 2.11. The cells were 
treated with medium containing the specified concentration of various xenobiotics for 
24hrs. After the treatment, the medium was removed and the cells were washed with 1x 
PBS. The cells were scraped off the flasks and collected for centrifugation at 300g for 
1min. Total RNA was extracted from the treated cells using RNeasy Mini kit and reverse 
transcription of the both GAPDH and hMRP4 transcripts were carried out using reverse 
transcription system according to manufacturers instructions. After the first strand 
cDNA synthesis, the relative quantities of GAPDH and hMRP4 transcripts in each 
 47
treatment were quantified using SYBR Green Real-Time PCR. The real-time PCR 
reaction mixtures were assembled and run as indicated in Table 2.4. The forward and 
reverse primers for both genes are stated in Table 2.5.  The relative quantity of GAPDH 
transcripts serves as the internal control. 
 
 
Table 2.4. SYBR Green real-time PCR reaction mixture and PCR conditions. 
SYBR Green Reaction Mixture 
Components Volume (µl)  
18µM Forward Primer 1.25  
18µM Reverse Primer 1.25  
SYBR Green Mastermix 12.5  
1st Strand cDNA 
(10X diluted) 5  
Nuclear Free Water 5  
Total Volume 25  
   
Real-Time PCR Conditions 
1 Cycle 50oC 2 minutes 
1 Cycle 95oC 10 minutes 
45 Cycles 95oC 0.15 minute 
 60oC 1 minute 




Table 2.5. List of primers used for reverse transcription and real-time PCR. 
Target Gene  Primer Sequence 
GAPDH Forward 5  GAAGGTGAAGGTCGGAGTC  3 
 Reverse 5  GAAGATGGTGATGGGATTTC  3 
hMRP4 Forward 5  ATTATTGATGAAGCGACGGC -3 
 Reverse 5  GCAAAACATACGGCTCATCA  3 
 
 
2.15. Statistical Analysis 
All statistical analyses were done using One-Way ANOVA (equal variance assumed). 
The data were expressed as mean ± standard errors of the mean (S.E.M). A p-value of 
less than 0.05 is considered significant. 
 
 
2.16. Site-Directed Mutagenesis 
Site-directed mutagenesis was carried out using Quikchange® Site-Directed Mutagenesis 
kit according to the suppliers (Stratagene) protocol. All complimentary mutagenic 
primers were designed using Stratagenes web-based primer design program and 
purchased from Sigma-Proligo. The sequences of the mutagenic primers (mutated 
residues underlined) are listed in Table 2.6. In each mutagenesis reaction, 50ng of 
template, 125ng of each of the appropriate sense and anti-sense primers were used (Table 
2.7). All desired mutations were determined by sequence analysis. 
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Table 2.6. List of mutagenic primers for site-directed mutagenesis. 
Underlined nucleotides represent mutated core sequences of respective response element. 
Mutagenic Primer Primer Sequence Annealing Tm (oC) 
1st AhR Mut Sense 5'-cccagagtgctaggattatagATAC gagccattgtgcccagcccag-3 68
oC 
1st AhR Mut Anti-sense 5'-ctgggctgggcacaatggctcGTAT 
ctataatcctagcactctggg-3' 68
oC 
2nd AhR Mut Sense 5'-gaattaaaagtgagataattggtcggATAC ggtggtacatgcctgtaatcctagca-3' 67
oC 
2nd AhR Mut Anti-sense 5'-tgctaggattacaggcatgtaccaccGTAT 
ccgaccaattatctcacttttaattc-3' 67
oC 
2nd PXR Mut Sense 5'-ctccatgacaatcatttggcttcaaaaattatcag tattCAGGcttggagcctttgattttgatttttg-3' 68
oC 
2nd PXR Mut Anti-sense 5'-caaaaatcaaaatcaaaggctccaagCCTGaata 
ctgataatttttgaagccaaatgattgtcatggag-3' 68
oC 
1st RAR Mut Sense 5'-gggtggatatgaagagcagctgctAGTT ttgttaaggtagccacagaaatga-3' 67
oC 













Table 2.7. Mutant hMRP4 promoter constructs were generated using the indicated 




(50ng) Primer Used (125ng) 
Mut AhR 1-pGL3 M4B-pGL3 2
nd
 AhR Mut Sense &  
2nd AhR Mut Anti-sense 
Mut AhR 2-pGL3 M4A-pGL3 2
nd
 AhR Mut Sense &  
2nd AhR Mut Anti-sense 
Mut AhR 3-pGL3 Mut AhR 2-pGL3 1
st
 AhR Mut Sense &  
1st AhR Mut Anti-sense 
   
Mut PXR 1-pGL3 M4B-pGL3 2
nd
 PXR Mut Sense &  
2nd PXR Mut Anti-sense 
Mut PXR 2-pGL3 M4A-pGL3 2
nd
 PXR Mut Sense &  
2nd PXR Mut Anti-sense 
   
Mut RAR 1-pGL3 M4A-pGL3 1
st
 RAR Mut Sense &  















3.1. Prediction of Putative Nuclear Receptor Response Elements 
Following the cloning of M4A promoter region, the ~2kb hMRP4 promoter was first 
analyzed for putative nuclear receptor response elements using default search algorithm 
followed by the manual search algorithm of MatInspector. The predicted nuclear receptor 
response elements are shown in Figure 3.1. MatInspector default search algorithm 
predicted one Aryl Hydrocarbon Nuclear translocator (ARNT) homodimer, one Retinoic 
acid receptor (RAR) and two Pregnane X receptor (PXR) / Constitutive Androstane 
receptor (CAR) binding sites.  
 
Next, sequences of response elements characterized in promoter studies were manually 
entered into search algorithms of MatInspector. These experimentally characterized 
nuclear receptor binding sites included AhR elements (Sun et al., 2004), ER elements (De 
Luca, 1991), GR elements (Schoneveld et al., 2004), PXR elements (Kast et al., 2002) 
and RAR elements (De Luca, 1991). The manual search identified one additional GR and 
two additional AhR/ARNT heterodimer binding sites. No additional ER, PXR, ARNT or 
RAR response elements were found with exception to those predicted by the default 
configurations. The sequences of these putative nuclear receptor elements identified by 
both the default and the manual search are all summarized in Table 3.1. 
 
Based on these putative nuclear receptors sites, a series of truncated hMRP4 promoter 
constructs were generated as described in Section 2.6. These truncated promoter 
constructs were systematically generated to exclude certain putative nuclear receptor 
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response elements in order to examine their possible transcriptional contributions towards 
hMRP4 promoter activity in subsequent truncation studies (Section 3.7). 
 
 
Table 3.1. Putative nuclear receptor response elements 
Nucleotides which are highly conserved (i.e. Ci-value > 60) to the consensus matrix are 
underlined. The consensus index vector (Ci-value) represents the conservation of the 
individual nucleotide positions in the nucleotide distribution matrix as numerical values. 
The maximum Ci value of 100 is reached by a position with total conservation of one 
nucleotide, whereas the minimum value of 0 only occurs at a position with equal 
distribution of all four nucleotides and gaps (Frech et al., 1993). Core sequences used in 
MatInspector are shown in caps. (+) and (-) indicate that the matching sequences are 
found on the sense or anti-sense strand respectively. N represents any nucleotides. The 
translational start site was designated as +1. 
Response Elements Position Strand Sequence 
AhR/ARNT 
Heterodimer -2126 to -2120 (+) tnGCGTg 
 -1452 to -1446 (+) tnGCGTg 
    
ARNT Homodimer -979 to -965 (+) gaacccaCGTGtcgt 
    
RAR Halfsite -1764 to -1759 (-) aGGTCa 
    
PXR Halfsite / CAR 
Halfsite -1812 to -1802 (+) caTGAActtgg 
 -1225 to -1215 (+) ttTGAActtgg 
    




Figure 3.1. Prediction of putative nuclear receptor response elements 
A) Schematic representation of the putative nuclear receptor response elements 
within hMRP4 promoter region as predicted by MatInspector (Section 2.5). 
B) Schematic representation of the truncated promoter constructs (M4A to M4E). In 
this study, five promoter constructs encompassing different regions of the hMRP4 
promoter were generated by PCR and cloned upstream of the luciferase reporter 
gene within the promoterless pGL3-basic (pGL3) reporter vector. The translation 
start site was designated as +1. TSS, transcriptional start site. 
Promoter Region of Human MRP4 
M4A-pGL3 (1981 bp) 
Luciferase 
Luciferase M4C-pGL3 (756 bp) 
Luciferase M4D-pGL3 (446 bp) 
























3.2. Basal Transcriptional Activities of the hMRP4 Promoter 
Constructs 
 
After obtaining the series of hMRP4 promoter-pGL3 constructs (i.e. M4A-pGL3 to M4E-
pGL3) as described in Section 2.4 and 2.6, it is essential to determine that these promoter 
constructs were transcriptionally active before any xenobiotics screening can be done. 
Hence their basal transcriptional activities were determined. All the promoter-pGL3 
constructs together with the promoterless pGL3 vector (negative control) were transiently 
transfected into HepG2 and Huh7 cell lines as described in Section 2.11. No xenobiotics 
treatments were given in this experiment. The relative luciferase units (RLUs), equivalent 
to the amount of luciferase (i.e. reporter) expressed after normalizing to the amount of â-
galactosidase produced in transient transfection studies were determined (Section 2.13). 
The mean RLUs were used as a measure for the basal transcriptional activities of the 
promoter-pGL3 constructs. The results as shown in Figure 3.2 indicate that all the 
hMRP4 promoter constructs (i.e. M4A-pGL3 to M4E-pGL3) are transcriptionally active 























































































Figure 3.2. Basal activity of the various hMRP4 promoter constructs transfected into A) HepG2 and B) Huh7 cells.  
The promoter-pGL3 reporter plasmids (M4A-pGL3 to M4E-pGL3) and pGL3-basic vector were each co-transfected into A) HepG2 
cells or B) Huh7 cells with pcDNA6/LacZ plasmid as transfection control. Cells were grown in DMEM (10%FBS) for 48 hrs. Cell 
lysates were assayed for luciferase activity, which was normalized to respective â-galactosidase activity. The normalized activity of 
the promoterless pGL3 vector was then assigned as one and the activities of all other constructs were expressed as fold of this 
(Corrected Luciferase Activity). Data shown represent corrected luciferase activity ± S.E.M of three independently transfected 
samples. * denotes statistically significant difference (p<0.05) between promote constructs and promoterless pGL3 vector while # 
denotes statistically significant difference in basal promoter activity from the previous truncated promoter construct by One-way 
ANOVA. 
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3.3. Nuclear Receptor Expression Profiles of HepG2 and Huh7 
In order to use cell lines as in vitro models to study the effects of activated nuclear 
receptors on the regulation of hMRP4 gene, the expression levels of various nuclear 
receptors in HepG2 and Huh7 cells were examined using RT-PCR (Section 2.8 and 2.9). 
The expression of various nuclear receptor transcripts in HepG2 and Huh7 cells are 
tabulated in Table 3.2.  
 
Both HepG2 and Huh7 cells were found to have similar nuclear receptor expression 
profiles. HepG2 was found to express somewhat high levels of AhR, ARNT, RARá, 
RARã, GRá and GRâ. However, while RXRá was expressed at an intermediate level, 
both RARâ and PXR were only expressed at low levels. No detectable CAR transcripts 
were found to be expressed in HepG2. In the same experiment, Huh7 was found to 
express rather high levels of AhR, ARNT, RARá, RARâ, RXRá, GRá and GRâ. RARã 
was found be expressed at an intermediate level while both PXR and CAR were found to 
be expressed at low levels. No RT-PCR products were detected in all the negative 
controls where reverse transcriptase was omitted. Hence, this indicated that there was no 
genomic DNA contamination in the total RNA extractions.  
 
Based on the nuclear receptor expression profiles, initial xenobiotics screening of AhR, 
RAR and GR activators were performed firstly in HepG2 cells followed by an additional 
screening in Huh7 cells as both cell lines expressed these nuclear receptors. Since both 
PXR and CAR were found to be expressed at low levels only in Huh7 cell line, initial 
screening of PXR and CAR activators were performed only in Huh7 cell line.  
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Table 3.2. Expression levels of nuclear receptor transcripts in HepG2 and Huh7  
Total RNA extraction and RT-PCR of the nuclear receptor transcripts were performed as 
described in Section 2.8. To exclude genomic DNA contamination, RT-PCR reaction 
without reverse transcriptase served as negative control for all the nuclear receptors 
examined while â-Actin served as the positive control. RT-PCR products were size 
fractionated on 1.2% agarose gel and visualized by staining with ethidium bromide 
(Section 2.9). Bands were scored using a scale of undetectable (-), low (+), intermediate 
(++), high (+++) or very high levels of products (++++).  
Nuclear Receptor HepG2 Huh7 
â-Actin ++++ ++++ 
AhR ++++ ++++ 
ARNT ++++ ++++ 
RARá ++++ ++++ 
RARâ + +++ 
RARã +++ ++ 
RXRá ++ +++ 
PXR + + 
CAR - + 
GRá ++++ ++++ 
GRâ ++++ +++ 
All Negative Controls - - 
  



















3.4. Effects of Nuclear Receptor Activators on Cell Viability (MTS 
Assay) 
 
Before the initial screening of nuclear receptor activators (i.e. xenobiotics) on their ability 
to activate hMRP4 promoter activity, it was necessary to ensure that the highest 
concentrations of each xenobiotic used did not compromise cell viability significantly. 
Hence, CellTiter 96® AQueous one solution cell proliferation assay (MTS assay) was 
performed on HepG2 and Huh7 cells after 48 hours of xenobiotic treatments at 10ìM and 
1ìM for all xenobiotics tested with exception of PB which was used at 1000ìM and 
100ìM (Section 2.10). In experiments where there were no significant reduction in cell 
viability between treated and untreated cells at 10ìM for the xenobiotics tested and 
1000ìM for PB, results at 1ìM for the xenobiotics tested and 100ìM for PB were not 
shown. The effect of DMSO on cell viability was also examined to ensure that the solvent 
used to dissolve all the xenobiotics in this study did not affect cell viability. Untreated 
cells maintained in DMEM (10% FBS) was used as controls and the average MTS assay 
reading for the control was set at 100%. The effects of nuclear receptor activators on cell 
viability are summarized in Table 3.3. 
 
The results showed that only clotrimazole (CTZ) significantly reduced (p < 0.05) Huh7 
cell viability at 10ìM. However, when 1ìM of clotrimazole was tested, there was no 
significant reduction in cell viability observed. All other xenobiotics examined did not 
have any effect on the viability of the HepG2 and Huh7 cells at concentrations up to 
10uM. For treatment with PB, concentrations as high as 1mM did not affect cell viability.  
 It was also noted that DMSO treatment up to 0.1% (v/v) showed no significant reduction 
of cell viability in Huh7 cells. This indicated that the solvent used is not toxic to the cells. 
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In summary, the highest concentration of nuclear receptor activators that can be used for 
subsequent transfection studies was 10ìM for all xenobiotics with exception of 
clotrimazole which was used at 1ìM and PB which was used at 1mM.   
 
 
Table 3.3. Effects of nuclear receptor activators on cell viability. 
Cell viability was determined as described in Section 2.10. The cell viability of untreated 
cells was set as 100%. The cell viability of each treatment was expressed as a ratio of the 
absorbance at 490nm of treated cells to that of untreated cells in percentage. Data are 
expressed as mean percentage cell viability ± S.E.M of six independently treated samples. 
* denotes statistically significant difference (p<0.05) between treated and untreated cells 













HepG2 - Untreated - 100.00 ± 6.61 
  DMSO 0.02% (v/v) 101.96 ± 1.25 
 AhR Â-Napthoflavone (BNF) 10 91.91 ± 4.82 
  3-Methylcholanthrene (3MC) 10 117.83 ± 1.72 
 RARá All-trans retinoic acid (ATRA) 10 87.17 ± 3.22 
  13-cis retinoic acid (13cisRA) 10 88.75 ± 0.72 
 GR Dexamethasone (DEX) 10 100.50 ± 5.12 
  Prednisolone (PRED) 10 94.33 ± 5.41 
Huh7 - Untreated - 100.00 ± 2.64 
  DMSO 0.1% (v/v) 104.22 ± 0.89 
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 AhR Â-Napthoflavone (BNF) 10 113.14 ± 6.04  
  3-Methylcholanthrene (3MC) 10 103.23 ± 3.39 
 RARá All-trans retinoic acid (ATRA) 10 104.32 ± 0.69 
  13-cis retinoic acid (13cRA) 10 100.58 ± 2.01 
 RXR 9-cis retinoic acid (9cRA) 10 90.53 ± 2.45 
 GR Dexamethasone (DEX) 10 103.48 ± 2.19 
  Prednisolone (PRED) 10 91.21 ± 1.19 
 PXR Pregnenolone-16á-carbonitrile (PCN) 10 91.40 ± 1.37 
  Rifampicin (RIF) 10 112.30 ± 2.14 
  Mifepristone (RU486) 10 91.30 ± 1.38 
  Clotrimazole (CTZ) 10 80.40 ± 1.01* 
   1 113.67 ± 0.78 
 CAR Phenobarbital (PB) 1000 116.43 ± 4.13  











3.5. Induction of hMRP4 Promoter Activity 
3.5.1. Effects of Nuclear Receptor Activators on hMRP4 
Promoter Activity 
 
After assessing the toxicity and determining the highest concentration of various nuclear 
receptor activators to be used, initial screening of these xenobiotics for their ability to 
modulate hMRP4 promoter activity was performed in HepG2 and Huh7 cells. Results of 
the preliminary screening are shown in Figure 3.3.  
 
The data obtained showed that AhR activators (BNF and 3-MC) and RAR activators 
(ATRA and 13cRA) were able to induce hMRP4 promoter activity significantly in both 
HepG2 and Huh7 cells. In addition, PXR activators (PCN, RU486, RIF and CTZ) were 
found to induce hMRP4 promoter activity significantly but to a lesser extent in Huh7 
cells. Preliminary screening of GR activators in HepG2 cells did not lead to any induction 
of the hMRP4 promoter activity. Hence, further screening of GR activators in Huh7 cells 
was not performed. Screening of two CAR activators (PB and DAS) in Huh7 cells also 
did not yield any significant induction of hMRP4 promoter activity. In summary, AhR 
activators (BNF and 3-MC), RAR activators (ATRA and 13cRA) as well as PXR 
activators (PCN, RU486, RIF and CTZ) are possible exogenous modulators of hMRP4 































































































































Figure 3.3. Effects of nuclear receptor activators on hMRP4A promoter activity. 
Transient transfection and reporter assays were performed in A) HepG2 and B) Huh7 cells as described in Section 2.11 and 2.13. 
M4A-pGL3 promoter construct and pcDNA6/LacZ plasmid were used for transfection. The concentrations of the xenobiotics 
used were 0.1ìM with the exception of 1mM for PB. The mean relative luciferase unit (RLU) of the vehicle control was set as 1. 
Induction is expressed as a ratio of relative luciferase units of treated samples to that of the vehicle control (DMSO). Data are 
presented as mean fold induction ± S.E.M of three independently transfected samples. * denotes statistically significant 
difference (p<0.05) between treatment and DMSO control by One-way ANOVA. 
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3.5.2. Effects of Nuclear Receptor Activators on Endogenous 
hMRP4 Gene Expression in HepG2 and Huh7 Cells 
 
In order to further verify the results obtained in Section 3.5.1. The effects of 
representative NR activators on the levels of endogenous hMRP4 gene expression were 
also examined. HepG2 and Huh7 cells were treated with various xenobiotics at the 
specified concentration for 24 hrs. Subsequently, the levels of endogenous hMRP4 
transcripts in treated samples were detected by SYBR Green real-time PCR and 
normalized to untreated samples. Figure 3.4 shows the levels of endogenous hMRP4 
transcripts induced after xenobiotics exposure.  
 
In HepG2 cells (Figure 3.4 A), the observed data showed that 3-MC (10ìM) can result in 
a low but significant increase of hMRP4 transcripts. In addition, ATRA and 13cRA were 
also able to increase hMRP4 transcripts at 10ìM and 1ìM. Results from these RAR 
activators also indicated a dose-dependent induction of hMRP4 transcripts in HepG2 
cells. 
 
Similarly, data from Huh7 cells (Figure 3.4 B) showed that BNF (0.1ìM) and 3-MC 
(10ìM) were able to induce hMRP4 gene expression significantly. In addition, it was 
also observed that the RAR ligand 13cRA (1ìM) and the PXR ligand PCN (10ìM) can 
result in significant induction of hMRP4 gene expression. In conclusion, these results 
further verified the possible roles of AhR, RAR and PXR activators in the regulation of 
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Figure 3.4. Effects of nuclear receptor activators on the expression of endogenous hMRP4 gene.   
A) HepG2 and B) Huh7 cells were treated with different nuclear receptor activators at the indicated concentration for 24hr. Cells were 
harvested, total RNA were prepared and quantitative real time PCR was carried out as described in Section 2.14. In this experiment,  
2-ääCt of the vehicle control (DMSO) is set as 1. Induction is expressed as a ratio of the treated samples to that of the DMSO control. 
Data are presented as mean fold induction ± S.E.M of three independent samples. * denotes statistically significant difference (p<0.05) 
between treatment and DMSO control by One-way ANOVA. 
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3.6. Dose Dependent Induction of hMRP4 Promoter Activity 
In this section, dose-dependent induction of hMRP4A promoter activity were performed 
so as to select one representative activator from each class of nuclear receptor activators 
(Table 2.3) and determine the corresponding optimum concentration to use in subsequent 
truncation studies. Twenty-four hour after transfection, cells were treated with increasing 
concentrations of xenobiotics for 48 hrs. Dose-dependent induction was observed for all 
the xenobiotics examined. It was found that BNF and 3-MC induced the highest 
transcriptional activity of hMRP4A promoter activity at 0.1ìM and 10ìM respectively 
(Figure 3.5 A and B). As for RAR and PXR activators, it was observed that ATRA and 
13cRA as well as PCN induced the highest hMRP4A promoter activity at 10ìM (Figure 
3.5 C, D and E). Based on these observations, BNF (0.1ìM), ATRA (10ìM) and PCN 






































































































































































































Figure 3.5. Dose-dependent induction of hMRP4 promoter activity.   
Transient transfection and reporter assays were performed in Huh7 cells as described in Section 
2.11 and 2.13. M4A-pGL3 promoter construct and pcDNA6/LacZ plasmid were used for 
transfection. Cells were then treated with DMSO (vehicle control) or increasing concentrations of 
the indicated xenobiotics (A) BNF, (B) 3MC, (C) ATRA, (D) 13-cis RA and (E) PCN for 48hrs. 
The concentration of DMSO control did not exceed 0.1% (v/v). The mean relative luciferase unit 
(RLU) of the vehicle control was set as 1. Induction is expressed as a ratio of relative luciferase 
units of treated samples to that of the vehicle control (DMSO). Data are presented as mean fold 
induction ± S.E.M of three independent samples. * denotes statistically significant difference 
(p<0.05) between treatment and DMSO control by One-way ANOVA. 
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3.7. Effects of BNF, ATRA and PCN on the Transcriptional 
Activity of hMRP4 Truncated Promoter Constructs 
 
Truncation analysis was carried out to examine which region/s of the promoter 
contributes to the observed induction of hMRP4A promoter activity by AhR, RAR and 
PXR activators. The effects of each xenobiotic on the transcriptional activity of various 
hMRP4 truncated promoter constructs are shown in Figure 3.6.  
 
Treatment with BNF induced significant promoter activity in M4A-pGL3 (1.92 fold) and 
to a lesser extent in M4B-pGL3 (1.40 fold) (Figure 3.6 A). However, BNF treatment did 
not induce the activity of the shorter constructs, M4C-pGL3 (1.07 fold) and M4D-pGL3 
(0.95 fold).  
 
It is well documented that activated RXR can either form homodimers or function as a 
common heterodimerization partner for activated RAR and PXR (Glass and Rosenfeld, 
2000). Since the natural retinoid, 9-cis retinoic acid (9cRA), is a high affinity ligand for 
RXR, treatment with 9cRA was included to rule out the possibility of cross-activation by 
RXR homodimers. Therefore, in subsequent truncation analysis and over-expression 
studies, transfected cells were subjected to different treatment regimens (i.e. DMSO 
control treatment, combined ATRA or PCN with 9cRA treatment, ATRA or PCN 
treatment and 9cRA treatment). This is necessary to find out the optimum treatment 
which can induce the maximal hMRP4 promoter activity. The use of 9cRA as a specific 
ligand for RXR is common among laboratories that are involved in the study of the role 
of nuclear receptors in regulating transporters. Some of the studies include vitamin D 
receptor-dependent regulation of colon MRP3 (McCarthy et al., 2005) and farnesoid X 
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receptor-dependent transactivation of bile salt export pump (Ananthanarayanan et al., 
2001). 
 
It was observed that only M4A-pGL3 responded significantly to the combined ATRA & 
9cRA treatment (2.90 fold) as well as ATRA treatment (2.57 fold) (Figure 3.6 B). 
However, treatment with 9cRA alone did not induce any significant M4A-pGL3 
promoter activity. All other shorter truncated promoter constructs examined (M4B-pGL3, 
M4C-pGL3 and M4E-pGL3) did not respond to any of the treatment regimen.  
 
As shown in Figure 3.6 C, treatment with PCN alone resulted in a modest and yet 
significant induction of both M4A-pGL3 and M4B-pGL3 promoter activities at ~1.3 fold. 
In addition to that, combined treatment with PCN & 9cRA resulted in an even higher 
induction of M4A-pGL3 and M4B-pGL3 promoter activities at 1.52 and 1.75 fold 
respectively. For both treatment regimens, the promoter activities observed in M4A-
pGL3 for were not statistically different from that observed in M4B-pGL3. It is also 
noted that treatment with 9cRA alone did not induce any significant M4A-pGL3 and 
M4B-pGL3 promoter activity. The shorter promoter constructs (M4C-pGL3 and M4D-
pGL3) did not respond significantly to any of the treatment regimen. 
 
Results from this truncation analysis suggest that AhR and PXR response elements 
responsible for the observed transcriptional induction of hMRP4 promoter are present in 
M4A-pGL3 and M4B-pGL3 constructs, while the RAR response element is present in 

























































































































Figure 3.6. The effect of AhR, RAR and PXR activators on the transcriptional 
activity of truncated hMRP4 promoter constructs.  
Each truncated promoter-pGL3 constructs were co-transfected into Huh7 cells with 
pcDNA6/LacZ plasmid as described in Section 2.11. Cells were then treated with DMSO 
0.02%-0.04% (Vehicle Control) or (A) 0.1ìM BNF or (B) 10ìM ATRA and/or 0.1ìM 
9cRA or (C) 1ìM PCN and/or 0.1ìM 9cRA for 48 hrs. For each truncated promoter-
pGL3 construct, the mean relative luciferase unit (RLU) of DMSO control was set as 1. 
Induction is expressed as a ratio of relative luciferase units of treated truncated promoter-
pGL3 construct to that of its DMSO control. Data are presented as mean fold induction ± 
S.E.M of three independent samples. * denotes statistically significant difference (p<0.05) 
between treatment and DMSO control. # denotes statistically significant difference 
(p<0.05) between single xenobiotic treatment with combined xenobiotics treatment. ^ 
denotes statistically difference between M4A-pGL3 and M4B-pGL3 activity from the 
same treatment by One-way ANOVA. In all experiments, inductions from M4D-pGL3 
were not significantly different from M4E-pGL3. Hence, only M4D-pGL3 was shown. 
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3.8. Nuclear Receptor Over-Expression Study 
To further establish the roles of human AhR, RAR and PXR in the transcriptional 
regulation of hMRP4 promoter, transient nuclear receptors over-expression experiments 
were performed to examine the effects of elevated nuclear receptors on the transcriptional 
activation of hMRP4 promoter activity in response to their respective activators. Nuclear 
receptor over-expression studies were conducted by transfecting M4A-pGL3 reporter 
plasmid and â-galactosidase expression plasmid into cells, in the presence or absence of 
plasmids encoding the necessary nuclear receptors as described in Section 2.12.  
 
Our data showed that AhR and ARNT over-expression (+AhR +ARNT) resulted in a 
significant increase in hMRP4A promoter activity (2.28 fold) (Figure 3.7 A). However, 
this increase in promoter activity was not significantly different from the experiment 
without AhR and ARNT (-AhR -ARNT) (1.96 fold).  
 
As mentioned in Section 3.7, four different treatments were implemented (i.e. DMSO 
control, combined treatment (ATRA/PCN & 9cRA) and single xenobiotic treatment 
(ATRA or PCN or 9cRA)) for RARá/RXRá and PXR/RXRá over-expression studies. 
Our data showed that in the absence of RARá and RXRá transient expression, M4A-
pGL3 responded significantly to the combined treatment as well as the ATRA treatment 
at 2.55 and 2.33 fold respectively (Figure 3.7 B). However, in the presence of RARá and 
RXRá transient expression, the two treatments significantly enhanced the hMRP4A 
promoter activity to 4.05 and 3.71 fold respectively. It is also noted that 9cRA treatment 
alone did not induce any substantial promoter activity in M4A-pGL3.   
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Similarly for PXR/RXRá over-expression studies, it was observed that in the absence of 
PXR and RXR transient expression, both the combined treatment as well as the PCN 
treatment induced hMRP4A promoter activity modestly at 1.66 and 1.35 fold respectively 
(Figure 3.7 C). However, in the presence of PXR and RXR transient expression, the two 
treatments further enhanced the hMRP4A promoter activity to 3.61 and 1.76 fold 
respectively. These further enhancements in promoter activities were statistically 
significantly different to that obtained without PXR and RXRá over-expression. This 
suggested the involvement of PXR/RXRá heterodimers in the modulation of hMRP4 
promoter activity. It is also noted that 9cRA treatment alone did not induce any 
significant promoter activity in M4A-pGL3. These results signify the dependency of the 
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Figure 3.7. The effect of nuclear receptor over-expression on hMRP4A promoter 
activity. 
Transient (A) AhR & ARNT or (B) RARá & RXRá or (C) PXR & RXRá over-
expression transfection and reporter assays were performed in Huh7 cells as described in 
Section 2.12 and 2.13. M4A-pGL3 promoter construct and pcDNA6/LacZ plasmid were 
used for transfection. After the two phases of transfection, cells were then treated with 
DMSO 0.02%-0.04% (Vehicle Control) or (A) 0.1ìM BNF or (B) 10ìM ATRA and /or 
0.1ìM 9cRA or (C) 10ìM PCN and/or 0.1ìM 9cRA for 48 hrs. For each experiment, the 
mean relative luciferase unit (RLU) of its vehicle control was set as 1. Induction is 
expressed as a ratio of relative luciferase units of treated promoter-pGL3 construct to that 
of its vehicle control (DMSO). Data are presented as mean fold induction ± S.E.M of 
three independent samples. * denotes statistically significant difference (p<0.05) between 
treatment and DMSO control, # denotes statistically significant enhanced induction 




3.9. Site-directed Mutagenesis of Putative Nuclear Receptor 
Response Element(s) 
 
Based on the above results, it is highly possible that hMRP4 promoter could be activated 
by xenobiotics via several nuclear receptor mediated pathways. In order to validate the 
involvement of AhR, RAR or PXR in the regulation of hMRP4 promoter, site-directed 
mutagenesis was performed to mutate the core nucleotide residues of the respective 
putative nuclear receptor response elements predicted previously. Figure 3.8 shows the 
schematic illustrations of the newly generated mutant hMRP4 promoter constructs and 
Table 3.4 shows the respective response elements and their altered residues. The mutant 
promoter constructs were then transfected into Huh7 cells and their transcriptional 
responsiveness to appropriate xenobiotics treatment were examined. 
 
Figure 3.9 shows a series of transfection with M4A-pGL3 or M4B-pGL3 or mutant 
promoter constructs in the presence of the indicated nuclear receptor expression plasmids. 
Following the treatment with BNF, it was observed that M4B-pGL3 has a significant 
induction of 1.54 fold (Figure 3.9 A). However, the corresponding mutated construct (i.e. 
Mut AhR 1) was not responsive to BNF treatment. As for M4A-pGL3, it has a significant 
induction of 2.06 fold versus its DMSO control. However, the mutated construct (i.e. Mut 
AhR 2) showed a significant reduction in its response to BNF when compared to wild-
type construct (M4A-pGL3). Despite the reduction in promoter activity, this construct is 
still inducible when compared to the corresponding DMSO control by One-way ANOVA 
analysis. The Mut AhR 3 construct with both AREs mutated was not responsive to BNF. 
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In response to ATRA and 9cRA treatment, M4A-pGL3 maintained a significant promoter 
induction of 3.83 fold versus its vehicle control (Figure 3.9 B). On the other hand, Mut 
RAR 1 showed a drastic reduction in promoter response to the activators. Despite the 
reduced response, this mutant RAR construct is still responsive to ATRA and 9cRA 
treatment when compared to the corresponding DMSO control.  
 
In the presence of PXR and RXRá expressing plasmids co-transfection, both M4A-pGL3 
and M4B-pGL3 have significant promoter induction of an approximately 3.7 fold 
compared to their vehicle controls. In contrast, both Mut PXR 1 and Mut PXR 2 showed 
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Figure 3.8. Wild-type and mutant hMRP4 promoter constructs with their mutated 
sites. 
Schematic representation of the wild-type hMRP4 truncated promoter constructs (M4A-
pGL3 and M4B-pGL3) and their respective mutant promoter constructs with indicated 
putative nuclear response element(s) mutated by site-directed mutagenesis. The presence 
of the desired mutations was determined by sequence analysis.  
ARE: AhR / ARNT response element, RRE: RAR response element, PRE: PXR response 
element,. Response element sequences in caps are core sequences which were 
subsequently mutated by site-directed mutagenesis. Boxed X represents response 






Table 3.4. Nuclear receptor response elements and their respective mutated residues. 
Underlined nucleotides represent mutated core sequences of respective response element. 
Nuclear 
Receptor Position Response Elements 
Mutated Response 
Elements 
AhR / ARNT -2126 to -2120 5-tnGCGTg-3 5- tnATACg-3 
 -1452 to -1446 5-tnGCGTg-3 5- tnATACg-3 
RAR -1764 to -1759 5-aGGTCa-3 5-aAACTa-3 



























































































DMSO 0.04% PCN (10ìM) + 9cRA (0.1ìM)
 
 
Figure 3.9. Human MRP4 promoter is regulated by several nuclear receptor 
mediated mechanisms. 
Huh7 cells were co-transfected with expression constructs for (A) AhR & ARNT, (B) 
RARá & RXRá and (C) PXR & RXRá and subsequently with M4A-pGL3 or M4B-
pGL3 or respective mutant promoter constructs and pcDNA6/LacZ plasmids as described 
in Section 2.12. After transfection, cells were treated with the indicated xenobiotics for 
48 hrs. For each experiment, the mean relative luciferase unit (RLU) of its vehicle control 
was set as 1. Induction is expressed as a ratio of relative luciferase units of treated 
promoter-pGL3 construct to that of its vehicle control (DMSO). Data are presented as 
mean fold induction ± S.E.M of three independent samples.  
* denotes statistically significant difference (p<0.05) between treatment and DMSO 
control, # denotes statistically significant reduction of mutant promoter activity versus 
activator-treated M4A-pGL3 activity, ^ denotes statistically significant reduction of 










4. Discussion  
Like multi-antibiotics resistance in the treatment of bacteria infections, multidrug 
resistance phenomenon has been a key drawback in anti-cancer and anti-viral therapy. A 
great deal of biomedical research has been focused on improvising new strategies to 
overcome the multidrug resistance phenotype. The discovery of P-gp in 1976 by Juliano 
and Ling marked the beginning of the identification of a large family of drug pumps, 
including MRPs, which are responsible for the reduced efficacies of anti-cancer and anti-
viral treatments. Over the years, several members of the MRP family were cloned and 
their functions characterized. However, information on the mechanism/s of modulating 
the temporal and spatial expression of these transporter pumps is incomplete and limited.  
 
Recent in vivo and in vitro studies showed increasing evidences to suggest that these 
MRPs can be transcriptionally regulated by activated nuclear receptors in response to 
xenobiotics exposure. To date, the mechanism involved in the regulation of the human 
MRP4 gene is poorly understood. Hence, the aim of this study is to elucidate the role of 
xenobiotics-activated nuclear receptors on the transcriptional activation of the human 
MRP4 promoter. In this study, AhR activators (BNF and 3-MC), RAR activators (ATRA 
and 13cRA) and PXR activators (PCN, RIF, RU486 and CTZ) were found to be capable 
of inducing transcriptional activity of hMRP4 promoter. In addition, results from NR 
over-expression studies and transfection with mutated promoter constructs further 
suggested that hMRP4 gene can be modulated by NR mediated mechanisms. 
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In this discussion, data from each individual sub-sections will be critically evaluated. 
Subsequently, the implications of the findings are discussed and additional future work 
are also suggested.  
 
 
4.1. Prediction of Putative Nuclear Receptors Response Elements 
Nuclear receptors are transcription factors that regulate gene expression at transcriptional 
level. They have the ability to recognize and bind to specific regulatory sequences within 
the promoter regions of its target genes, leading to the formation of a transcriptional 
complex via the recruitment of co-regulatory and accessory proteins, which in turn 
mediate the transcription of the downstream structural genes (Wang and LeCluyse, 2003). 
Hence, the identification of consensus nucleotide sequences (i.e. putative nuclear receptor 
response elements) in the promoter region serve as a starting point to elucidate the role of 
nuclear receptors in the regulating their target genes. 
 
In this study, the MatInspector program was used to analyze ~2kb of the hMRP4 
promoter sequence. This method is more versatile than the conventional IUPAC searches 
and it assigns a numerical value to the matches which is very useful in pre-selecting 
potential regulatory sites for gene regulation studies (Quandt et al., 1995). From the 
default and manual search algorithm, numerous nuclear receptor response elements were 
predicted along the length of the hMRP4 promoter (Figure 3.1 and Table 3.1). These 
predicted elements corresponded to nuclear receptors such as AhR, RAR and PXR that 
are known to regulate important phase I/II XMEs and transporters (Section 1.6)
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Although the response elements are predicted on the hMRP4 promoter region, their roles 
in regulating the promoter activity have to be determined experimentally. 
 
As MatInspector software utilizes a library of pre-defined matrix descriptions for protein 
binding sites to scan DNA sequences of unlimited length for consensus patterns. A 
possible inherent shortcoming of this software is its inability to identify novel nucleotide 
patterns that were newly discovered and not yet included into the matrix library (false 
negatives). Nevertheless, this can be overcome through the use of manual search option 
for novel response elements that are recently published. In addition, one major drawback 
of sequence analysis software packages, including MatInspector, is the identification of 
false positives. In MatInspector, putative nuclear receptor response elements are 
predicted by means of a scoring system. It assigns a quality rating to matches and thus 
allows quality-based filtering and selection of matches. However, it is beyond the power 
of the software to foretell if the predicted putative sites are functional within the cells. 
This can be explained by the fact that within eukaryotic cells, DNA is packed with 
histones. Depending on the status of histone acetylation, a response element in the 
promoter region of a target gene may not be accessible to the activated nuclear receptor 
hence renders the site non-functional in regulating the downstream gene. Therefore, the 
predictions must be compared with sufficient experimental data to assess the sensitivity 
of this method. It is important to note that there are some discrepancies between the 
predicted sites and the promoters responses to xenobiotics in the initial screening stage 
(Figure 3.1 and 3.3). Hence it is possible that GR and CAR elements are false positives.  
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4.2. Basal Transcriptional Activity of hMRP4 Promoter Constructs 
All the truncated promoter constructs examined were shown to possess basal promoter 
activity in both HepG2 and Huh7 cells (Figure 3.2). However, it is interesting to note that 
a truncation from M4A-pGL3 to M4B-pGL3 and M4C-pGL3 to M4D-pGL3 resulted in 
an increase in basal promoter activity. This suggests the presence of basal repressor 
elements within promoter regions of (-2438 to -1740) and (-1214 to -904) which were 
deleted in the truncation process. On the other hand, truncation of M4B-pGL3 to M4C-
pGL3 and M4D-pGL3 to M4E-pGL3 resulted in a slight decrease in basal promoter 
activity. This in turn suggests the deletion of basal transcriptional activator elements 
within promoter regions of (-1740 to -1214) and (-904 to -804). Indeed, based on the 
predictions obtained from MatInspector, several transcriptional repressors and basal 
activators were identified (Figure 4.1). The predicted repressor elements include E4BP4 
(-1916 to -1896; -1186 to -1166), RBP-JKappa/CBF1 (-1860 to -1846) and BCL6 (-1852 
to -1836) which are known to repress interleukin-1â (Chen et al., 1995), c-myc (Cooper 
et al., 2003) and ataxia-telangiectasia and  Rad3-related (ATR) gene (Ranuncolo et al., 
2007) respectively. The basal activator transcriptional elements predicted were 
steroidogenic factor 1 (SF1) (-1494 to -1482), nuclear factor Y (-1459 to -1445) and 
stimulating protein 1 (Sp1) (-826 to -810) which are reported to regulate the basal 
expression of human glycoprotein hormone alpha-subunit gene (Fowkes and Burrin, 
2003), human TLX3 gene (Borghini et al., 2006) and human cytidine deaminase genes 





Figure 4.1. Putative basal transcriptional activator and repressor elements on 
hMRP4 promoter as predicted by MatInspector.  
A) Schematic representation of the putative basal transcriptional activator and 
repressor elements within hMRP4 promoter region as predicted by MatInspector. 
B) Schematic representation of the putative basal transcriptional activator and 
repressor elements within each truncated promoter constructs (M4A to M4E). 
Some basal transcriptional elements were deleted during the generation of the 
deletion promoter constructs. The translation start site was designated as +1. TSS, 
transcriptional start site. 
Promoter Region of Human MRP4 
M4A-pGL3 (1981 bp) 
Luciferase 
Luciferase M4B-pGL3 (1280 bp) 
Luciferase M4C-pGL3 (756 bp) 
Luciferase M4D-pGL3 (446 bp) 























4.3. Nuclear Receptor Expression Profiles of HepG2 and Huh7 
Cells 
 
In order to use cell lines as in vitro models to study the roles of nuclear receptors on the 
transcriptional regulation of hMRP4 promoter, it would be necessary to first determine 
that the cell lines used express the nuclear receptors of interest. Both HepG2 and Huh7 
cell lines were chosen for this study because they are of hepatic origin and have been 
frequently used for the examination of nuclear receptor-mediated transporter induction 
studies (Ananthanarayanan et al., 2001; Schrenk et al., 2001; Kast et al., 2002; Teng et 
al., 2003). Results indicated in Table 3.2 confirm that HepG2 and Huh7 cells express the 
nuclear receptors of interest except for CAR which was not detected in HepG2 cells. 
Hence, initial screening of different nuclear receptor activators was done in HepG2 and 
Huh7 cells while promoter studies investigating the effects of PXR and CAR activators 
were only carried out in Huh7 cells. 
 
 
4.4. Effects of Nuclear Receptor Activators on hMRP4 Promoter 
Activity and Endogenous hMRP4 Gene Expression 
 
An initial screening of the various classes of nuclear receptor activators was conducted to 
identify xenobiotics that can significantly induce the hMRP4 promoter activity. The 
ability of a xenobiotic to induce hMRP4 promoter activity was examined by two different 
approaches; transient transfection (Section 2.11) and RT-real time PCR (Section 2.14). 
These screens also serve as a way to narrow down the classes of nuclear receptor 
activators for further evaluation.  
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Results from transient transfection showed that the ~2kb hMRP4 promoter region was 
significantly induced by AhR activators (BNF and 3-MC) and RAR activators (ATRA 
and 13cRA) in both HepG2 and Huh7 cells (Figure 3.3 A & B). The ability of AhR and 
RAR activators to induce hMRP4 promoter activity is supported by the observed 
increased expression of hMRP4 transcripts which were detected by RT-real time PCR 
(Figure 3.4 A and B).  The experimental data obtained is consistent with the prediction of 
two AhR and one RAR response elements within the hMRP4 promoter (Section 3.1, 
Figure 3.1). Hence, this suggests that the predicted AhR and RAR response elements are 
likely to be functional.  
 
From Section 3.1, the MatInspector program also predicted two PXR halfsite/CAR 
halfsite (Figure 3.1). Hence PXR (PCN, RU486, RIF and CTZ) and CAR (PB and DAS) 
activators were also included in this initial screening. The results obtained from transient 
transfection revealed that the ~2kb hMRP4 promoter is responsive to PXR activators but 
not to CAR activators (Figure 3.3 B). Similarly, results from RT-real time PCR also 
indicate that PCN, but not PB, can increase hMRP4 gene expression in Huh7 cells 
(Figure 3.4 B). Although Assem et al (2001) showed that PB was able to induce MRP4 in 
HepG2 cells using RT-PCR, our observation could be explained by the fact that the low 
level of CAR transcripts in Huh7 cells (Table 3.2) might not be sufficient to elicit a 
significant MRP4 induction upon PB and DAS treatments. Hence, the observed increased 
in hMRP4 promoter activity and hMRP4 gene expression by PXR activators indicates 
that the two predicted response elements are probably PXR halfsites but not CAR 
halfsites. Compared to the levels of induction by AHR and RAR activators, the induction 
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by PXR activators is much smaller. This could be explained by the fact that there is only 
a low level of PXR expression in Huh7 cells as compared to high levels of AhR, ARNT, 
RARá and RXRá expression (Table 3.2). It was also found that GR activators (DEX and 
PRED) did not yield any significant induction of hMRP4 promoter activity (Figure 3.3 A), 
despite high levels of GRá and GRâ detected in Huh7 cells (Table 3.2). This indicates 
that the novel GR site predicted in Section 3.1 is not functional and is likely to be a false 
positive from MatInspector manual search program.  
 
 
4.5. Role of AhR/ARNT on the Transcriptional Regulation of 
hMRP4 Promoter Constructs 
 
Two AhR / ARNT response elements (AREs) at positions -2126 to -2120 and -1452 to     
-1446 were predicted to be present on the hMRP4 promoter (Table 3.1, Figure 3.1). 
Experimentally, it was observed that the promoter can indeed be induced by the AhR 
activators, BNF and 3-MC. The induction was dose-dependent with the highest promoter 
activity observed at 0.1ìM BNF and at 10ìM 3-MC (Figure 3.5 A and B).  
 
In AhR/ARNT over-expression studies, experiments with and without co-transfection of 
AhR and ARNT expressing plasmids showed similar level of promoter induction (Figure 
3.7 A). This indicates that the AhR and ARNT receptors are not the limiting factor for 
hMRP4 promoter induction in Huh7 cells. Hence elevated AhR and ARNT 
concentrations do not further increase the hMRP4 promoter activity. This is supported by 
the RT-PCR results which showed high levels of AhR and ARNT transcripts in Huh7 
cells. The levels were comparable to that of the â-actin control (Table 3.2).  
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Truncated constructs were used to determine if both the predicted elements were 
responsive to activated AhR/ARNT. In truncation analysis, M4A-pGL3, M4B-pGL3, 
M4C-pGL3 and M4D-pGL3 were transfected into Huh7 cells to examine their 
responsiveness to BNF treatment (Figure 3.6 A). Constructs which did not have any of 
the two predicted elements (M4C-pGL3 and M4D-pGL3) were found to be unresponsive 
to BNF. Deletion of the ARE at -2126 to -2120 led to a much reduced response to BNF 
indicating that both AREs are functional and are synergistic in activity. 
 
In order to further verify that both of the two AREs are functional and that each of them 
contribute partially to the total observed activity for the ~2kb hMRP4 promoter (M4A-
pGL3), site-directed mutagenesis was carried out to systematically mutate the core 
sequences of the AREs (Figure 3.8). The construct Mut AhR 2 (with a wild-type -2126 to 
-2120 ARE and a mutated -1452 to -1446 ARE) showed a significant reduction in 
promoter activity versus its parent construct (M4A-pGL3) (Figure 3.9 A). However, it 
was still inducible by BNF. This observation suggests that while the -1452 to -1446 ARE 
is rendered non-functional by mutation, the unaltered ARE site (-2126 to -2120) is still 
capable of contributing partially to the transcriptional activation ~2kb hMRP4 promoter. 
The response to BNF was totally abolished only when both sites were mutated. These 
data thus confirmed that both AREs are functional and contribute synergistically towards 
the response of the hMRP4 promoter to activated AhR/ARNT. 
 
In addition, it is worth noting that a putative ARNT homodimer binding site was also 
predicted to be present at position -979 to -965 (Figure 3.1). In this study, this site was 
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not found to be active. This is probably due to the fact that neither AhR nor ARNT is 
capable of recognizing its response element as homodimers (Matsushita et al., 1993; 
Soprano and Soprano, 2003). Furthermore, no ARNT agonist has been described. Hence 
the possibility of ARNT homodimer in regulating the transcriptional activity of hMRP4 
promoter was excluded in this study. 
 
 
4.6. Role of RARá/RXRá on the Transcriptional Regulation of 
hMRP4 Promoter Constructs 
 
Prediction using the MatInspector program indicated that there is a putative RAR 
response element (RRE) on the hMRP4 promoter. The RAR halfsite is located at position 
-1764 to -1759 (Table 3.1, Figure 3.1). Results obtained from transient transfection and 
RT-real time PCR analysis showed that the hMRP4 promoter is responsive to RAR 
activators such as natural retinoids (i.e. ATRA and 13cRA). In the subsequent dose-
dependent studies, it was also observed that the hMRP4A promoter responded to ATRA 
and 13-cisRA treatment in a dose-dependent manner with maximal response at 10ìM for 
both retinoids (Figure 3.5 C and D). Dependency of this induction by retinoids on the 
RAR and RXR receptors was also established by performing RARá/RXRá over-
expression studies. Experiments with co-transfection of RARá and RXRá expressing 
plasmids showed a considerably higher level of hMRP4 promoter induction in response 




Truncated constructs were used to determine if the predicted RAR halfsite was indeed the 
element that evoked the response to retinoids. The full length promoter, M4A-pGL3 and 
various truncated constructs, M4B-pGL3, M4C-pGL3, M4D-pGL3 and M4E-pGL3 were 
transfected into Huh7 cells to examine their responsiveness to ATRA and/or 9cRA 
treatment. It was observed that the combined ATRA and 9cRA treatment induced a 
significantly higher hMRP4A promoter activity of 2.90 fold as compared to 2.57 fold 
from the ATRA treatment (Figure 3.6 B). Although ATRA is a ligand for RAR and RXR, 
it is shown in this study that the inclusion of RXR specific ligand (9cRA) in the 
combined treatment can further enhance the hMRP4A promoter activity. However, 
treatment with 9cRA did not have any effect on the M4A-pGL3 promoter activity. These 
observations suggest that the observed hMRP4A promoter induction was due to 
RARá/RXRá activation, but not RXRá/RXRá homodimers. All other shorter truncated 
constructs which do not have the putative RAR halfsite was unresponsive to all the 
treatments (Figure 3.6 B). These results thus indicate that the RRE at position -1764 to     
-1759 is indeed functional and the induction of the promoter is dependent on 
RARá/RXRá activation.  
 
To further ascertain the involvement of the RRE at position -1764 to -1759 on the 
regulation of hMRP4 promoter activity, site-directed mutagenesis was carried out to 
mutate the core residues of the putative RRE (Figure 3.8). As shown in Figure 3.9 B, the 
mutation of core sequences in the putative RRE (-1764 to -1759) resulted in a significant 
reduction in the response of the Mut RAR 1 construct to RAR activators compared to its 
parent construct (M4A-pGL3). This indicates that the putative RRE is responsible for the 
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observed M4A-pGL3 promoter induction from combined retinoids treatment. Despite the 
substantial drop in promoter activity, the Mut RAR 1 construct still retained a small but 
statistically significant induction of 1.41 fold versus its vehicle control. One possible 
explanation for this observation is that the site-directed mutagenesis of the RRE did not 
result in the complete abolition of the RRE in Mut RAR 1. Therefore in the presence of 
RARá and RXRá over-expression, this insufficiency might allow some activated 
RARá/RXRá complex to bind and resulted in a small but statistically significant 
induction observed with the Mut RAR 1 construct. 
 
 
4.7. Role of PXR/RXRá on the Transcriptional Regulation of 
hMRP4 Promoter Constructs 
 
To examine the role of PXR and RXRá in the transcriptional regulation of hMRP4 
promoter construct, the MatInspector algorithm was used and this led to the prediction of 
two PXR/CAR halfsites at positions -1812 to -1802 and -1225 to -1215. (Table 3.1, 
Figure 3.1). As discussed above in Section 4.4, the longest hMRP4 promoter construct 
was responsive to PXR activators but not to CAR activators. This implies that only 
activated PXR/RXRá complex could bind the respective halfsites and activate hMRP4 
promoter activity. Hence, the PXR/CAR halfsites were referred to as PXR response 
elements (PREs) in this study. 
 
From the dose-dependent studies, it was observed that PCN gave a gradual dose-
dependent induction despite the increasing concentrations of PCN used (Figure 3.5 E). 
Given the low abundance of PXR transcripts in Huh7 cells, it is likely that the 
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concentration of PXR is the limiting factor in the transcriptional activation of hMRP4 
promoter activity in Huh7 cells (Table 3.2). Indeed when PXR/RXRá was over-expressed, 
there was considerably higher level of hMRP4A promoter induction than in experiments 
without PXR and RXRá over-expression. Thus hMRP4 promoter activity is dependent on 
PXR and RXRá concentrations within the cells.  
 
Experiments were also carried out to determine if both predicted PREs were responsible 
for the induction by PXR ligands. Truncated promoter constructs were generated such 
that M4A-pGL3 contains both PREs, M4B-pGL3 contains one PRE (-1225 to -1215) and 
the remaining three constructs (M4C- to M4E-pGL3) containing no putative PRE (Figure 
3.1). It was observed that both M4A-pGL3 and M4B-pGL3 responded to xenobiotic 
treatments, while the shorter constructs (M4C- to M4E-pGL3) did not. Our data showed 
that the combined PCN and 9cRA treatment is able to yield a significantly higher level of 
promoter induction in both M4A-pGL3 and M4B-pGL3 constructs as compared to PCN 
treatment alone (Figure 3.6 C). These results suggest that the inclusion of 9cRA in the 
treatment probably activates RXRá to heterodimerize with activated PXR, thereby 
enhancing the hMRP4 promoter activity. It is important to note that 9cRA treatment 
alone did not activate M4A-pGL3 and M4B-pGL promoter activity and this excluded the 
involvement of RXRá/RXRá homodimers in the observed promoter induction. It is also 
interesting to note that the deletion of one PRE (-1812 to -1802) in M4B-pGL3 did not 
reduce the inducible promoter activity significantly. This observation suggests that the 
PRE at position -1812 to -1802 is not likely to be functional and could be a false positive 
from the MatInspector prediction. In addition, data also revealed that the truncation of 
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M4A-pGL3 to M4B-pGL3 resulted in a slight increase in the promoter activity of the 
shorter promoter construct when exposed to combined PCN and 9cRA treatment. This 
observation is consistent with the deletion of basal repressor elements that are present in 
the deleted region (-2438 to -1740) as discussed in Section 4.2.  
 
To confirm the functionality of the predicted PREs in the transcriptional regulation of 
hMRP4 promoter, site-directed mutagenesis was first carried out on M4B-pGL3 and 
M4A-pGL3 to mutate the core sequences of the PRE at position -1225 to -1215 to 
generate Mut PXR 1 and Mut PXR 2 respectively (Figure 3.8). Both mutant promoter 
constructs (Mut PXR 1 and Mut PXR 2) failed to response to PCN indicating that the 
PRE at position -1225 to -1215 is required for the PXR/RXRá mediated activation. In 
addition, the observation also confirmed that the predicted PRE at position -1812 to -
1802 is not functional since Mut PXR 2 was not responsive to PCN despite having an 
unaltered PRE at this position. Hence mutation of this PRE (-1812 to -1802) was not 
carried out. Taken together, these data strongly suggest that the PRE at position -1225 to 
-1215 but not -1812 to -1802 is responsible for the PXR/RXRá mediated activation of the 
hMRP4 promoter. 
 
4.8. Implications of Findings 
4.8.1. Cholestatic Liver Diseases 
Cholestatic liver diseases account for a large proportion of chronic liver aliments in 
adults and children. They are also the leading indications for liver transplantation in all 
age groups. Cholestatic liver diseases are characterized by the impaired bile flow leading 
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to the retention of toxic bile constituents in the liver, resulting in hepatotoxicity and liver 
injuries (Sokol et al., 2006). Numerous in vitro experiments and animal models of 
cholestasis have demonstrated that rodent MRP4 are induced under cholestatic conditions 
(Assem et al., 2004; Denk et al., 2004; Wagner et al., 2005). Moreover, the up-regulation 
of MRP4 protein in human liver have also been reported in children diagnosed with 
progressive familial intrahepatic cholestasis (PFIC) (Keitel et al., 2005) as well as in 
patients with primary biliary cirrhosis (Zollner et al., 2007). This observed up-regulation 
of MRP4 proteins may represent an adaptive and important compensatory mechanism to 
limit bile acid-induced liver injury (Zollner et al., 2007). Our present findings suggest 
that hMRP4 can be regulated by AhR, RAR and PXR-mediated pathways. These findings 
may have new implications in the treatment of cholestatic liver diseases. Currently, the 
first-line treatment for patients with chronic cholestatic diseases is through the use of 
ursodeoxycholic acid (UDCA). Although the mechanism(s) of action in humans are still 
undefined, it is suggested that UDCA can improve bile acid transport and/or 
detoxification (Marschall et al., 2005). With our new findings, it is therefore logical to 
suggest that the co-administration of UDCA and exogenous compounds (such as AhR, 
RAR or PXR agonists) might improve clinical outcome. Ligand-activated NRs enhance 
the coordinated induction of phase I and II XMEs (such as CYP1A, CYP2B, CYP3A, 
SULT, GST and UGT) as well as transporters (such as MRP4) to increase the metabolism 
and elimination of toxic bile constituents and xenobiotics from the liver. Thus the 
combined treatment with UDCA and NR activators might provide an improved 
therapeutic intervention to the treatment of chronic cholestatic liver diseases.  
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4.8.2. Acquired Multidrug Resistance 
In cellular assays, MRP4 has been shown to confer resistance to anti-viral nucleoside 
analogs such as PMEA, AZT and ganciclovir. In addition to anti-viral agents, MRP4 is 
also a resistance factor for anti-cancer nucleoside-based agents including 6-MP and 6-TG 
as well as MTX and camptothecins (e.g. topotecan) (Lee et al., 2000; Wijnholds et al., 
2000; Chen et al., 2002). In addition to its broad resistance profile, the wide tissue 
distribution of hMRP4 in the body together with its inducible nature suggests that the 
pump has the potential to broadly affect drug accumulation hence resulting in drug 
resistance. In recent years, nuclear receptor activation by xenobiotics is a major concern 
for clinical practice especially when several drugs are co-administered (Wang and 
LeCluyse, 2003). Our findings that hMRP4 can be regulated by several NR-mediated 
pathways may have implications in the acquired multidrug resistance phenomenon when 
drug(s) are co-administrated.  
 
In mice, it has been demonstrated that hepatic MRP4 can be up-regulated upon exposure 
to CAR activators (Assem et al., 2004; Wagner et al., 2005). In a separate study using 
MRP4-/- mouse model, it was shown that MRP4 is an endogenous resistance factor for 
nucleoside-based analogs and protects bone marrow, thymus, spleen and intestine from 
nucleoside analogs-induced damage (Belinsky et al., 2007). Taken together, murine 
MRP4 can be induced via NR-mediate pathway and can function in vivo as an 
endogenous resistance factor to affect in vivo tissue sensitivity towards nucleoside-based 
agents. It is therefore logical to propose that human MRP4 can be regulated through NR-
mediated pathway upon xenobiotic exposure (which is demonstrated in this study) and 
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subsequently function in vivo to confer resistance to therapeutic agents that are MRP4 
substrates. In this regard, it is thus suggested that patients exposure to xenobiotics, such 
as NR activators that are known to induce hMRP4 expression, during the course of 
nucleoside-based anti-viral or anti-cancer treatment must be avoided to prevent undesired 
acquired drug resistance. Alternatively, the development and the utilization of specific 
transporter inhibitor (e.g. specific MRP4 inhibitor) or nuclear receptor antagonists might 
provide alternative means to alter drug disposition and to improve therapeutic efficacies 
of anti-viral and anti-cancer treatments.  
 
 
4.9. Future Work 
The findings of this study have strongly suggested that the two AREs (-2126/-2122 and -
1452/-1448), one PRE (-1225/-1215) and RRE (-1764/-1736) are functional. Through the 
use of transient transfection and reporter system, activated AhR/ARNT, RARá/RXRá 
and PXR/RXRá were implicated to modulate hMRP4 gene expression in response to 
appropriate xenobiotics exposure. However, the involvement of AhR/ARNT, 
RARá/RXRá and PXR/RXRá in the transcriptional regulation of hMRP4 promoter can 
be further confirmed through the establishment of physical binding of the activated 
nuclear receptors to their respective response elements. This can be performed by 
Electrophoretic Mobility Shift Assays (EMSA) on the truncated promoter constructs as 
well as the mutant promoter constructs obtained from site-directed mutagenesis. 
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Besides using promoter-reporter constructs to understand the regulation of hMRP4 
promoter by nuclear receptors activators, the expression level of endogenous hMRP4 
protein in response to xenobiotics can also be investigated. By combining new 
information on the hMRP4 protein expression with existing data on the regulation of 
human phase I/II enzymes by xenobiotics, it would provide insight for a coordinate up-
regulation of human phase I /II enzymes and hMRP4 protein leading to an integrated 
pathway of drug metabolism and elimination in humans. 
 
 
5. Conclusion  
In this study, several putative nuclear receptor response elements were predicted to be 
present on the ~2kb hMRP4 promoter sequence. These response elements were 
experimentally tested for their contribution towards hMRP4 promoter activity. Screening 
of various classes of nuclear receptor activators revealed that AhR, RAR and PXR 
activators were able to significantly induce hMRP4 promoter activity. In addition, 
nuclear receptors over-expression studies established the dependency of nuclear receptors 
in the regulation of hMRP4 promoter activity. 
 
Truncation analysis was carried out to determine the functionality of the putative 
response elements in the deleted promoter regions. This together with the site-directed 
mutagenesis approach led to the confirmation of the functionality and contribution of 
each of the putative nuclear receptor response elements towards the hMRP4 promoter 
activity. In conclusion, two ARE (-2126/-2122 and -1452/-1448), one PRE (-1225/-1215) 
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and RRE (-1764/-1736) were found to be involved in the transcriptional activation of 
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Sequence of the proximal hMRP4 promoter (translational start site is designated as +1). 
Sequence was obtained from the GenBank entry NT_009952. 
 
 
-2438 gattatgggc ttgtacagcc tggagtgcag tggcaccttc tttttttttt tgagacggag  
-2378 tttcactctt gttgccaagc tggagtgcag tgggatgatc tcggctcact gcaacctccg  
-2318 cctcctgggt tcaagtgatt cttctgcctg aggttcctga gtagctggga ttacaggcat  
-2258 ccaccaccac acccagataa ttttttgtat ttttagtaga gatggggttt caccatgttg  
-2198 gccaggctgg tctcgaactc ctgacgtcag gtgattcacc tgcctcagcc tcccagagtg  
-2138 ctaggattat aggcgtgagc cattgtgccc agcccagtgg gcaccttctt aactccttgt  
-2078 agcctggaac tcctgggcta aagccatcct cctgtctcag cctctcgagt agctgggact  
-2018 acaagggtac gccaccacac ctgggctaat ttttaaaact tttggtagag acagagcctc  
-1958 actatgctgg ctagcctgtg cttgactttt aaatatgtgt ttgtgtaagg ctttctttaa  
-1898 aagctattaa ctatactatt ttagcaaata tacatgggaa attatcaagg aacaataaaa  
-1838 tgatcttgtt ccaagcacca tgaacttgga gcctttcatt ttttttcatt cagggtggat  
-1778 atgaagagca gctgctgacc ttgttaaggt agccacagaa atgactgaag acttagaggt  
-1718 gggagtacac aagcttggaa caagattttg ttcattcatt cctacagcca ttcaaccagc  
-1658 atattctggg cacttctcat gcacactggc catccaccag ggagacaggc catgcttaga  
-1598 cataggctta ttgcaaatca tgttttatcc tttcttggct ctaagactgg acaagttctg  
-1538 cctttcagct tcaccttcct catctataaa gtaaggataa ccttgaatgg ggcactgata  
-1478 gaattaaaag tgagataatt ggtcgggcgt ggtggtacat gcctgtaatc ctagcacttt  
-1418 gggaggccac ggtgggagga tcacttgagc ctaggagttt gagaccagcc tgggcaacaa  
-1358 agtgagaaat tatcaaggaa caataaaatg atcttattac aaagaaaacc aaattctcaa  
-1298 acatgcatga aatatgaaga aaataaacct ccatgacaat catttggctt caaaaattat  
-1238 cagtatttga acttggagcc tttgattttg atttttgcat ctctacaaaa attacaaaat  
-1178 atgagccggg tgtggtggcg ggtgcctgta gtcctagcta cttaaactga gttgggagga  
-1118 ttgcttgagc cctgggaggt cgagggtgca atgagccata atcgtgacac tgtgtgtgag  
-1058 actgccacac acacacacac acacacacac tagtgaggct acgcactcag aaatgcacat  
-998 gaacatcact ggtattctgg aacccacgtg tcgtttgcca ctgttatctg ttaggcttta  
-938 gggcttgacg acagaaatca tcaggcagtc tctctttcct cttatattcc tttcccaatc  
-878 taagggggca gcaaaaagct cagaggtcca ccgtagcatg caacatgtga gatgcctaaa  
-818 gcccgccccc atcgacgaca gcattcatcc atctcccgaa ttcatctggg tcatactctc 
-758 gagttacccg gctttcttga ggtcttgcag ctctacaagg ataatctgtg gctaaacttt  
-698 gctgtcgtcc aaggtcaaat gtttggctca caggttgaag agcctcccat ggcaccgtcg  
-638 tttggtcctg agaagggaaa ggcgcccagg gggcgggctg ctagagcacg aggcagctgt  
-578 ctcccagtct tcccaaaccc gtagccgagg gggcgtttct gcggcgcagg ggcgggcaca  
-518 gccgacgcct ccctgctcca ccttctgtgt cggcgcctag actcggatag tgaatttcgg  
-458 a 
 
 
